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ABSTRACT

Vitronectin is a human circulatory protein that is recruited to the extracellular matrix
(ECM) during tissue remodeling pathways linked to injury, inflammation, and tumor
metastasis. Whereas circulating vitronectin is monomeric, the tissue-associated form is
multimeric and contains multivalent binding sites for both cell-surface receptors and
components of the extracellular matrix. In addition, matrix-associated vitronectin
directly regulates plasmin-regulated matrix proteolysis through the localization and
stabilization of the serine protease inhibitor, plasminogen activator inhibitor type-1 (PAI1). As a component of the ECM, vitronectin adopts a pro-adhesive role, providing a
unique regulatory link between cell adhesion and pericellular proteolysis. The
mechanism by which vitronectin interconverts between a monomeric, circulating protein
and a multimeric ECM component remains to be established. Vitronectin shows a high
degree of conformational flexibility, and in vitro studies demonstrate that a number of
chaotropic agents and macromolecular ligands like PAI-1 are able to induce the
multimerization of vitronectin into higher-order forms. The induced multimeric form of
vitronectin shows similar ligand-binding properties to that of the matrix-associated form,
with a potential for multivalent interactions with biological partners including cellsurface receptors and ECM components. The following dissertation serves to summarize
a graduate research project designed to address the working hypothesis that PAI-1
represents a physiological cofactor for the conversion of vitronectin from a circulating,
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monomeric form to a matrix-associated, “activated” form. PAI-1-binding to
vitronectin induces the formation of higher-order complexes that display altered
adhesive properties distinct from the circulating (monomeric) form of vitronectin.
These altered adhesive properties arise from the formation of multivalent binding sites
for both cell surfaces and components of the ECM. Formation of vitronectin/PAI-1
complexes follows a step-wise assembly process that is dependent on protein
concentration and time, ultimately leading to an increased accumulation of vitronectin
at the cell-matrix interface. To address this hypothesis, biophysical studies were
designed to evaluate the mechanism of assembly of PAI-1/vitronectin complexes and the
pathway leading to multimerization of vitronectin. These studies were performed in
parallel with cell- and matrix-binding experiments to establish a correlation between PAI1-induced multimerization with enhanced adhesive properties and and conversion of
vitronectin into a matrix-associated form.

iii

TABLE OF CONTENTS
Chapter

Page

1.

BACKGROUND INFORMATION AND INTRODUCTION
TO RESEARCH AIMS ......................................................................................1
Introduction and Project Overview ..................................................................1
Discovery of Vitronectin as an Adhesive Component of Blood ......................3
Structural Organization and Ligand-Binding Sites of Vitronectin................3
The Somatomedin B domain........................................................................4
The Connecting Segment..............................................................................8
The Central Domain ...................................................................................10
The C-Terminal Domain ............................................................................11
Biological Functions of Vitronectin.................................................................12
Vitronectin is an Adhesive Component of the Pericellular
Environment................................................................................................12
Vitronectin Regulates Thrombosis and Fibrinolysis ...............................16
Vitronectin Regulates the Immune Response of Complement ...............18
Vitronectin and Embryonic Development ................................................19
Vitronectin in Wound Healing and Disease..............................................20
Distribution of Vitronectin in Circulation and Tissues .................................21
Statement of a Scientific Problem .............................................................25
Conformational Flexibility of Vitronectin – Testing the
Mechanisms of Activation ................................................................................25
Working Hypothesis ...................................................................................28
Research Aims.............................................................................................28
Aim 1: To test the effects of PAI-1-induced multimerization
on the interaction of vitronectin with cell-surface integrins and
components of the ECM .......................................................................30
Aim 2: To evaluate the effects of PAI-1-induced multimerization
of vitronectin in a living cell system using human fibroblasts ..........30
Aim 3: To study the mechanism of assembly of higher-order
vitronectin/PAI-1 complexes ................................................................31

2.

PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 PROMOTES
THE SELF-ASSOCIATION OF VITRONECTIN INTO COMPLEXES
EXHIBITING ALTERED INCORPORATION INTO THE
EXTRACELLULAR MATRIX.......................................................................33
Introduction.................................................................................................33
Materials and Methods...............................................................................35
Proteins and Antibodies .......................................................................35

iv

Size Exlusion HPLC..............................................................................35
SDS-PAGE and Western Blotting .......................................................36
Fluorescence Measurements ................................................................37
Cell Binding Assays ..............................................................................38
Matrix Binding Assays .........................................................................38
Integrin Binding Assays .......................................................................39
Results ..........................................................................................................39
Size Exlusion HPLC Was Used to Monitor the Formation of
Large Complexes Resulting from PAI-1 Binding to Vitronectin .....39
PAI-1 Effects on Vitronectin Enhance Its Interaction with
Extracellular Matrices..........................................................................43
The Time Course of PAI-1-Induced Multimerization of
Vitronectin Parallels Enhanced Association with the ECM .............45
Enhancement of Binding of Vitronectin/PAI-1 Complexes to
ECM is Dependent on Ionic Strength .................................................49
Multimerization Promoted by PAI-1 Binding Enhances the
Interaction of Vitronectin with Cell Surface Receptors....................53
Discussion.....................................................................................................58
3.

PLASMINOGEN ACTIVATOR INHIBITOR-1 PROMOTES THE
RELOCALIZATION OF VITRONECTIN TO THE
EXTRACELLULAR MATRIX.......................................................................65
Introduction.................................................................................................65
Materials and Methods...............................................................................67
Proteins and Antibodies .......................................................................67
Cell Culture ...........................................................................................67
Iodination of Vitronectin......................................................................68
Binding and Degradation of Vitronectin ............................................68
Immunofluorescence Microscopy........................................................69
Isolation of ECM from Fibroblast Monolayers..................................70
Results ..........................................................................................................71
PAI-1 Binding Promotes Increased Processing of Vitronectin
By Human A1-F Fibroblasts ................................................................71
PAI-1 Promotes Increased Binding of Vitronectin to Human
Fibroblast Monolayers..........................................................................73
Binding of Vitronectin/PAI-1 Complexes to Fibroblast
Monolayers is Dependent on the Presence of Active PAI-1 ..............76
Immunofluorescent Localization of Vitronectin and PAI-1
Demonstrates the Effects of Complex Formation on
Fibroblast Association and Degradation ............................................79
Turnover of PAI-1/Vitronectin Complexes by A1-F
Fibroblasts is Partially Integrin-Dependent.......................................85
Enhancement of Vitronectin Binding to Fibroblast Monolayers
is Dependent on the Native Structure of PAI-1..................................87

v

Discussion.....................................................................................................88
4.

A MECHANISM FOR ASSEMBLY OF COMPLEXES OF
VITRONECTIN AND PAI-1 FROM SEDIMENTATION
VELOCITY ANALYSIS ..................................................................................92
Introduction.................................................................................................92
Materials and Methods...............................................................................95
Purification and Fluorescent Labeling of Vitronectin.......................95
Mutagenesis, Expression and Purification of Recombinant
PAI-1 ......................................................................................................96
Sedimentation Velocity Experiments ..................................................97
Hydrodynamic Modeling of Sedimentation Velocity Data ...............97
Multi-Signal Analysis of Sedimentation Data for FluorescentlyLabeled PAI-1/Vitronectin Mixtures ..................................................99
Results ........................................................................................................100
Characterization of PAI-1 and Vitronectin......................................100
Mixtures of PAI-1 and Vitronectin Form Reversible HigherOrder Complexes ................................................................................102
Formation of Higher-Order Complexes Occurs in a
Concentration-Dependent Fashion....................................................109
Multi-Signal Sedimentation Velocity Analysis Confirms the
Binding of Two PAI-1 Molecules to Vitronectin..............................112
Oligomeric Forms of Vitronectin Persist at Long Incubation
Times ....................................................................................................119
Salt Effects Demonstrate the Potential Role of Ionic Interactions
In the Formation of a Vitronectin/PAI-1 Complex..........................120
Assembly of PAI-1/Vitronectin Complexes is Independent
of the Anti-Protease Activity of the Inhibitor...................................123
Discussion...................................................................................................127
Bibliography/List of References ..............................................................132
Vitae ...........................................................................................................147

vi

LIST OF TABLES
Table
1-I

Page
Deposition of vitronectin in injured/diseased tissue ......................................23

4-I

Sedimentation coefficients for PAI-1, vitronectin and PAI-1/
vitronectin complexes .....................................................................................103
4-II Assembly of PAI-1 and vitronectin into intermediate and higherorder complexes ..............................................................................................107
4-III Assembly of complexes between different recombinant forms of
PAI-1 and vitronectin .....................................................................................125

vii

LIST OF FIGURES
Figure
1-1
1-2
1-3
1-4
1-5
2-1
2-2
2-3
2-4
2-5
2-6
2-7
2-8
2-9
2-10
2-11

3-1
3-2
3-3
3-4
3-5
3-6

Page

Domain organization of vitronectin ..................................................................5
Vitronectin is linked to many biological functions ........................................13
Comparison of active and latent forms of PAI-1 ...........................................17
Models for evaluating the structural/functional activation of
vitronectin..........................................................................................................27
Schematic representing the working model to be investigated.....................29
Size-exclusion HPLC evaluation of PAI-1-induced multimerization of
vitronectin..........................................................................................................41
PAI-1 is detected in high molecular weight vitronectin complexes..............42
Complexes of vitronectin and PAI-1 associate with the ECM......................44
Vitronectin deposition into the ECM is dependent on PAI-1 binding .........46
Evaluation of the effects of multimerization of vitronectin on
binding to the ECM using tPA to neurtralize PAI-1 .....................................48
Effects of increase ionic strength on PAI-1-mediated binding of
vitronectin to ECM ...........................................................................................50
Fluorescence experiments using NBD-labeled PAI-1 demostrate that
PAI-1 binding to vitronectin is not influenced by ionic strength ................52
PAI-1 enhances the binding of radiolabeled vitronectin to smooth
muscle cells ........................................................................................................54
PAI-1-induced multimerization enhances the binding of vitronectin
to GPIIbIIIa.......................................................................................................56
Effects of EDTA, ionic strength, and addition of tPA on PAI-1mediated binding of vitronectin to GPIIbIIIa................................................57
A model for association of vitronectin into complexes with altered
adhesive properties ...........................................................................................62
SDS-PAGE analysis of iodinated-vitronectin.................................................72
Vitronectin degradation by human fibroblasts is dependent on
PAI-1 binding ....................................................................................................74
PAI-1 binding enhances the association of vitronectin with
fibroblast monolayers .......................................................................................75
Effect if chlorate treatment on vitronectin binding to fibroblast
monolayers in the presence and absence of added PAI-1 .............................77
Effect of tPA-mediated release of active PAI-1 on vitronectin
binding to fibroblast monolayers.....................................................................78
Effects of PAI-1-induced formation of higher-order complexes on the
cellular localization of vitronectin on human fibroblasts..............................80

viii

3-7
3-8
3-9

4-1
4-2
4-3
4-4
4-5
4-6
4-7
4-8
4-9
4-10
4-11

Immunofluorescent localization of vitronectin demonstrates enhanced
binding of higher-order PAI-1/vitronectin mulitmers to ECM....................83
Fluorescent microscopy demonstrates the co-localization of
vitronectin and PAI-1 on human fibroblasts..................................................84
Cell turnover and binding experiments demonstrate the role of integrins
And native PAI-1 in the turnover of vitronectin by fibroblasts ...................86
Sedimentation velocity analysis of PAI-1 and vitronectin
using SEDFIT ..................................................................................................101
Sedimentation velocity analysis of an equimolar PAI-1/vitronectin
mixture using SEDFIT ...................................................................................105
c(s) distribution analysis of equimolar mixtures of PAI-1 and
vitronectin........................................................................................................106
SV analysis to evaluate the concentration dependence of formation of
higher-order PAI-1/vitronectin complexes ...................................................110
Multisignal analysis of complex formation between fluorescentlylabeled vitronectin and PAI-1 using SEDFIT ..............................................114
Global multisignal analysis of a PAI-1/vitronectin mixture using
SEDPHAT........................................................................................................116
Multisignal analysis demonstrates the formation of a 2:1 PAI-1/
vitronectin complex at 6.5 S ...........................................................................118
Test for the formation of vitronectin oligomers as a function of time .......121
Test for the effects of NaCl concentration on the formation of
PAI-1/vitronectin complexes ..........................................................................122
c(s) distribution analysis of equimolar mixtures of mutant forms of
PAI-1 and human vitronectin ........................................................................124
Model for formation of multivalent complexes via the 6.5 S
PAI-1/vitronectin intermediate......................................................................130

ix

LIST OF SYMBOLS AND ABBREVIATIONS
AT-IIa
BSA
DMEM
ECM
ELISA
FBS
FITC
GAG(s)
HPLC
PAGE
PAI-1
PBS
RGD
RGDS
SMB
TCA
tPA
uPA
uPAR
VN
µM
RCL
Serpin
SV
SDS
RMSD

Antithrombin-thrombin complex
Bovine serum albumin
Dulbecco’s Modified Eagle Medium
Extracellular matrix
Enzyme-linked immunosorbent assay
Fetal bovine serum
Fluoroscein isothiocyanate
Glycosaminoglycan(s)
High pressure liquid chromatography
Polyacrylamide gel electrophoresis
Plasminogen activator inhibitor type-1
Phosphate buffered saline
Arginine-glycine-aspartate integrin binding locus
Arginine-glycine-aspartate-serine tetrapeptide
Somatomedin B domain
Trichloroacetic acid
Tissue-type plasminogen activator
Urokinase-type plasminogen activator
Urokinase receptor
Vitronectin
Micromolar
Reactive center loop
Serine protease inhibitor
Sedimentation velocity
Sodium dodecyl sulfate
Root mean square deviation

x

CHAPTER 1
BACKGROUND INFORMATION AND INTRODUCTION
TO RESEARCH AIMS

Introduction and Project Overview
The extracellular matrix (ECM) is an intricate system of proteins and polysaccharides
that serves as a scaffold for cellular activities such as attachment, migration, and invasion
[1,2]. Molecules that make up the ECM include integral components such as collagens,
laminins, and proteoglycans, as well as plasma-derived proteins that upon certain
biological stimuli become deposited into the tissue matrix [1-3]. The various components
of the ECM play active and complex roles in regulating the behavior of attached cells,
directly controlling cell shape, proliferation, differentiation, morphogenesis, movement,
and survival [2]. In pathological states, such as tissue wounding, inflammation, and
tumor metastasis, the normal composition and functioning of the ECM can be profoundly
perturbed in ways that can significantly affect the behaviors of surrounding cells [1-3].
Perturbations in the ECM occur through pathways of tissue remodeling that are carried
out by the combined efforts of proteolytic enzyme systems and multi-functional adhesive
proteins [2-5].
Tissue remodeling refers to transient or permanent alterations in the molecular
architecture of the ECM and occurs in a variety of physiological and pathological
processes, including ovulation, spermatogenesis, wound healing, inflammation, and
cancer [4]. Such alterations occur through processes that involve both breakdown and
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assembly of ECM components, resulting in significant changes in the structural
composition of the ECM and the behavioral signals that it presents to nearby cells [2-5].
In a recent review by Davis et al. [2], various mechanisms of tissue remodeling are
discussed that lead to the exposure of “matricryptic” cell/matrix-recognition sites, which
are not available in the mature, secreted forms of molecules making up the ECM. These
exposed matricryptic sites provide new, local signals that directly regulate cellular and
tissue responses to events like injury, inflammation, and cancer [2].
One of the most important examples of an ECM component that undergoes remodeling
and exposure of such matricryptic binding sites is the protein vitronectin. Vitronectin,
which is a glycoprotein found predominantly in circulation, becomes deposited into the
ECM of tissues following injury or tumor mestastasis by an unknown mechanism.
A working hypothesis of this laboratory suggests that multimerization of vitronectin is a
physiologically-triggered event that leads to the conversion of plasma (monomeric)
vitronectin into an adhesive form that readily associates with tissues. The work presented
here tests the proposal that interactions with certain biological ligands (here PAI-1) result
in the conversion of plasma vitronectin to an ECM-associated form that exhibits altered
adhesive properties. We suggest that this conversion results from a step-wise assembly
of vitronectin/ligand complexes that via multivalent interactions with matrix components
(like glycosaminoglycans) and cell-surface receptors (like integrins and urokinase
receptor) becomes tissue-associated. Here, the adhesive nature of vitronectin can be
utilized during processes like cell adhesion, migration, and invasion.
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To familiarize the reader with the subject matter of this work, below is an overview of
the structural and functional properties of vitronectin. This section leads into defining the
scientific problem to be addressed, followed by a description of the working hypothesis
and experimental objectives.

Discovery of Vitronectin as an Adhesive Component of Blood
Prior to the discovery of vitronectin, it was widely known that blood serum could be
used to support the binding and activities of many cell types. Partial separations of serum
lead to the discovery of a major component that served to support cells in culture [6-10].
This newly-discovered component was first named “serum spreading factor” [6] and
“epibolin” [8] – an name given to reflect the ability of this component to support
epithelial cell spreading and epiboly. In the years that followed, the serum component
became widely known under the name vitronectin “on the basis of its binding to glass and
its adhesive properties [9].” Since its discovery, vitronectin has become appreciated as
the main adhesive component in serum that supports cell attachment and proliferation in
culture. Over the past 20 years, the ability of vitronectin to support cell adhesion has
become more and more recognized as a key function that the protein serves in both blood
circulation as well as in the ECM of tissues.

Structural Organization and Ligand-Binding Sites of Vitronectin
As will be discussed in the section to follow, vitronectin is a multifunctional protein
that plays part in many diverse biological functions including development, wound
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healing, and cancer. This property of vitronectin is largely owed to the ability of the
glycoprotein to interact with a large list of biological ligands. This ability is linked to a
complex molecular organization, which has been elucidated by sequencing human and
rabbit cDNAs and by analyzing the exon-intron-organization of the human vitronectin
gene [11-15]. From this, vitronectin can be organized into four structural domains that
include: the somatomedin B (SMB) domain, the connecting segment, the central domain,
and the C-terminal heparin-binding domain (Figure 1-1). Binding sites within these
domains are responsible for interactions with various physiological ligands including
PAI-1, heparin, and the thrombin-antithrombin III complex, which have been determined
using techniques like limited proteolytic degradation, peptide mapping,
immunochemistry methods, domain swapping, and site-directed mutagenesis. Structural
studies of vitronectin have been carried out using computational modeling, NMR, and xray crystallography. The binding and structural properties mentioned here and how they
relate to each of the four structural domains of vitronectin are outlined below.

The Somatomedin B Domain—The amino terminal segment of vitronectin comprising
amino acids 1-44 is identical in sequence to the plasma protein somatomedin B (SMB), a
protein with no known function and most likely derived from limited proteolysis of fulllength vitronectin [16]. The SMB domain of vitronectin contains high-affinity binding
sites for two important fibrinolytic factores, PAI-1 and uPAR [17-21].
An interesting feature of the SMB domain is the presence of eight highly-conserved
cysteine residues that are interlinked through disulphide bonds, predicting an intricate
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PAI-1
uPAR

Heparin, Integrin αVβ5, GAGs, Complement,
Syndecan, Collagen, uPAR, PAI-1

T-AT III complex
Collagen

Plasminogen
Proteolytic
Cleavage site
(Arg379-Ala380)

Integrins
RGD
Sequence
(45-47)
----SMB
Domain
(1-44)

Connecting
Segment
(45-130)
N-gly (Asn67)

S-S

S-S

Cys137 Cys161 Cys196

Cys274

Central
Domain
(Hemopexin-like Repeat I)
(131-342)
N-gly (Asn150)

N-gly (Asn223)

++++
2-Phoshorylation sites (Ser362/Ser378)

2-Sulfation sites (Tyr56/Tyr59)
2-Phoshorylation sites (Thr50/Thr57)

N----C5---C9---------C19-C21---C25-----C31C32------C39

Cys411
Cys453
C-terminal HeparinBinding Domain
(Hemopexin Repeat II)
(343-459)

--

(8 S-S interlinked Cysteines)
Fig. 1-1. Domain organization of vitronectin. Structural domains include the SMB domain, the connecting segment,
the central domain, and the heparin-binding C-terminal domain. Shown at top at the proposed binding sites for several
ligands of vitronectin. Cysteines that are disulfide-linked are shown. Cysteine residues 196 and 411 (in boxes) are
have free sulfhydryls that are buried in the native structure. The oval with minus signs represents the acidic region in
the connecting segement and the one with plus signs represents the arginine/lysine-rich polycationic region of the
heparin-binding domain. Also shown are sites for sulfation, phosphorylation, and N-linked glycosylation, as well as the
proteolytic cleavage site that in related to the 2-chain form of vitronectin.
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compact structure [16,22]. The sequential positioning of the cysteines within the SMB
domain – Cys5-Cys9-Cys19-Cys21-Cys25-Cys31-Cys32-Cys39 – is found in several other
proteins, including megakaryocyte-stimulating factor (MSF), plasma cell membrane
glycoprotein PC-1 , autotoxin (ATX), and tumor cell surface antigen gp130, suggesting
that this domain represents a highly-conserved structural fold [23]. Using alaninescanning mutagenesis, Deng et al. [23] demonstrated that each of the eight conserved
cysteines within the SMB domain were critical in the binding and stabilization of PAI-1
in its active form. These observations indicate that correct disulfide linkages in the SMB
domain are required for PAI-1 binding. To carry this analysis further, techniques like xray crystallography, NMR, and disulfide mapping are currently being applied to
understand the role that these disulfide linkages play in the tertiary structure of the PAI-1binding SMB domain of vitronectin.
Recently, Kamikubo et al. [24] identified the disulfide bonds formed between cysteines
in a recombinant form of the SMB domain of human vitronectin. Their findings
suggested that the disulfide bonds are linked in an uncrossed, linear pattern, as: Cys5Cys9, Cys19-Cys21, Cys25-Cys31, and Cys32-Cys39. In contrast, x-ray crystallographic
studies of SMB domain in complex with PAI-1 suggested a crossed pattern of disulfides
(Cys5-Cys21, Cys9-Cys39, Cys19-Cys32, and Cys25-Cys31) that forms a novel disulfidebonded “knot” [25]. Unfortunately, both of these reports must be taken with caution as
they are based on information collected using recombinant (made in E. coli) forms of the
SMB domain.
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Recent studies from this laboratory investigating the structure and disulfide
arrangement of the SMB domain provide a much more convincing picture by evaluating
these features using SMB domain isolated from human plasma vitronectin [26,27].
Combined approaches using NMR, limited proteolysis, and mass spectrometry suggest a
crossed disulfide arrangement with the following assignments: Cys5-Cys9, Cys19-Cys31,
Cys21-Cys32, and Cys25-Cys39.
Until recently, no experimentally-solved structure for vitronectin had been reported. As
will be described later, vitronectin is extremely labile and prone to multimerization,
making it difficult to crystallize for x-ray diffraction studies. The first reported structure
for vitronectin came in July of 2003 when Robin Carrell’s research group at Cambridge
University (UK) presented a crystal structure for the SMB domain of vitronectin bound to
active PAI-1 with an rmsd value of 2.3 Ǻ [28]. The presented SMB structure represents a
novel protein fold, with the only secondary structure of the SMB domain being a singleturn α-helix and a single-turn 310-helix. The co-structure of SMB with PAI-1
demonstrates a potential mechanism through which vitronectin can bind and stabilize
PAI-1 in its active conformation. This proposed mechanism involves the binding of the
SMB domain across the E and F helices of PAI-1, which prevents a sliding movement of
strands 1 and 2 of the main β-sheet. The movement of these strands is associated with
the conformational transition of PAI-1 to its latent inactive form, and by preventing this
movement the SMB domain of vitronectin stabilizes the active conformation of PAI-1.
Interpretations of these findings must be taken with caution as again the structure
presented is that for a recombinant form of the protein [28].
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Our laboratory recently provided the first solution structure of the SMB domain at 2.29
Ǻ using 2-dimentional NMR methods to evaluate the domain that was isolated directly
from plasma vitronectin [27]. These findings were similar to those reported from the xray diffraction study describe above, in which the SMB domain contains only 2 elements
with a secondary structure. Again these structures consisted of a single-turn α-helix
(spanning residues 26-30) and a loosely defined 310 helix (spanning residues 36-38) with
the remainder of the SMB domain comprised of loops, some of which appear to be
flexible [27]. However, the two structures solved by these different methods do not
superimpose well, with different directional orientations of the α-helix in relation to the
310 helix, resulting in an RMSD between the two structures of greater than 8 Ǻ [27,28].
These differences may reflect variations in the methods used (x-ray crystallography
versus NMR), the form of SMB domains used (recombinant versus human forms), and/or
the type of sample analyzed (SMB domain in complex with PAI-1 versus the SMB
domain in its isolated form). Interestingly, both structural determinations were in
agreement with the findings of Deng et al. [23] that demonstrated the requirement for
specific residues (Asp22, Glu23, Leu24, Tyr27, and Tyr28) in the binding and stabilization of
PAI-1. Both solved structures demonstrate that these residues are properly aligned on the
α-helix of the SMB domain for optimal binding to PAI-1.

The Connecting Segment—Following the SMB domain, residues 45 through 130 make
up what is known as the connecting segment, or linker region of vitronectin [16].
Directly adjacent to the SMB domain at the N-terminal end of the connecting segment is
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an arginine-glycine-aspartate (RGD) sequence (residues 45-47) that mediates the
attachment and spreading of cells to the ECM through the binding to specific integrin
receptors [29,30]. Indeed, site-directed mutagenesis of the RGD sequence abolishes cell
adhesion to vitronectin [31]. Several integrins, including αVβ1, αVβ3, αVβ5, and
GPIIbIIIa, have been shown to mediate cell adhesion by interacting with the RGD
sequence on vitronectin [32-34].
Adjacent to the RGD sequence, the connecting segment of vitronectin has a stretch of
acidic amino acids (residues 53-64), including two sulfated tyrosine residues (Tyr56 and
Tyr59) [35]. This acidic region is important in the binding of vitronectin to the thrombinantithrombin III and collagen [36,37]. It has been suggested that the acidic region of
vitronectin also plays a role in the binding and neutralization of a poly-cationic (heparinbinding) domain on the opposite end of the protein, in a manner that serves to stabilize
the 3-dimensional structure of vitronectin. Within the acidic region of vitronectin there
are two phoshorylation sites, Thr50 and Thr57, which are specifically phosphorylated by
casein kinase II (CKII) [38]. Phosphorylation by CKII was shown to promote cell
adhesion onto vitronectin, via the αVβ3-phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (PKB) pathway [39]. Downstream of the acidic region, the connecting segment
of vitronectin contains a site (residue Asn67) for N-linked glycosylation and a putative
cross-linking site (Gln93) for transglutaminase [40,41]. Although there is no reported
structure for the connecting segment of vitronectin, this segment of the protein is
predicted to be in a loop conformation by the secondary structure prediction program
PHD [42].
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The Central Domain—Residues 131-342 comprise the central domain of vitronectin,
which together with the C-terminal domain show strong homology to hemopexin, a
heme-binding protein found in plasma [16,22]. Hemopexin contains a symmetrical twodomain structure connected by a flexible hinge region, with each domain containing four
homologous repeats [43]. Vitronectin contains only six typical hemopexin repeats with a
putative hinge region at Pro268. The central domain of vitronectin contains four of these
repeats, and threading algorithms predict this domain to adopt a full four-bladed βpropeller fold, similar to that seen in gelatinase A, collagenase, and hemopexin [42]. The
central domain contains four cysteine residues in a mixture of reduced and oxidized
forms [44,45]. Two cysteine residues, Cys137 and Cys161, form an intra-domain disulfide
bridge, whereas Cys 274 forms an inter-domain disulfide bridge with Cys453 located within
the C-terminal domain of vitronectin. This inter-domain bridge serves to link an
endogenously-cleaved 10-kDa fragment from the C-terminus of vitronectin with the rest
of the molecule (described in next section). The final cysteine (residue 196) of the
central domain is free and evidently inaccessible in the native form of vitronectin [44,45].
The central domain also contains two N-linked glycosylation sites at Asn150 and Asn223.
The only ligand-binding site attributed to the central domain is for plasminogen (residues
332-348), which spans over into the C-terminal domain of vitronectin [22] Aside from
the information gained from computer modeling described below, no structure for the
central domain has been solved experimentally.
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The C-Terminal Domain—The C-terminal domain (residues 347-459) of vitronectin
contains a basic region spanning approximately 30 amino acids (residues 348-376) rich in
arginine and lysine residues. This positively-charged region of vitronectin contains two
heparin-binding consensus sequences and plays a role in the binding and neutralization of
this important anti-coagulation factor. Interestingly, this heparin-binding domain is also
responsible for the binding of vitronectin to several other ligands, including the integrin
αVβ5 [46], sulfated glycosaminoglycans [47], syndecan [Wilkins-Port, 2004 #166],
complement components C5b, C6, C7, C8, C9 [48], plasminogen [49], PAI-1 [49-51],
uPAR, and collagen [37,52].
Directly downstream of the heparin binding domain is a proteolytic cleavage site
between Arg379 and Ala380 [53,54]. Susceptibility of cleavage at this site is dependent on
the presence of methionine or threonine at position 381 [53,54]. Cleavage occurs by an
unidentified protease and results in the release of 10-kDa fragment of vitronectin [55].
As mentioned above, Cys453 is disulfide-linked to Cys274 in the central domain, and this
bond holds the 10-kDa fragment of vitronectin to the remaining molecule. A second
cysteine (Cys411) within the C-terminal domain is free and buried [42].
Within the C-terminal domain of vitronectin, there are two potential phosphorylation
sites at serines 362 and 378. Protein kinase C (PKC) phosphorylates at Ser362 which
causes an attenuation in the cleavage of vitronectin by plasmin [56]. Protein kinase A
(PKA), which is released from platelets upon activation, specifically phosphorylates
vitronectin at Ser378 [57]. Circular dichroism studies demonstrated that phosphorylation
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by PKA at Ser378 alters the conformation of vitronectin and results in decreased binding
of the protein to PAI-1 and plasminogen [58].
The C-terminal domain contains two of the six hemopexin-like repeats found within
vitronectin. As with the central domain, the only structural clues regarding the Cterminal domain of vitronectin come from computer modeling. Using threading, Xu et al.
[59] predicted the C-terminal domain to form one-half of a 4-bladed β-propeller fold.
Inter-domain docking of the central and C-terminal domains using GRAMM
demonstrated the presence of a groove lined with known heparin-binding residues.

Biological Functions of Vitronectin
Vitronectin, through its ability to interact with both cells and proteins that control
coagulation, fibrinolysis, and humoral defense, represents a unique regulatory link
between adhesion and proteolytic cascades that are involved in the maintenance of
homeostasis. Vitronectin has been linked to the regulation of several biological
processes (Figure 1-2), several of which are described below.

Vitronectin is an Adhesive Component of the Pericellular Environment—Vitronectin
has long been known for its ability to mediate cell adhesion and proliferation. Early
immunofluorescence studies demonstrated the presence of vitronectin in focal adhesions
of cells cultured in media supplemented with serum [13]. In fact, the majority of cell
attachment activity in serum-containing media is mediated by vitronectin, and to a lesser
extent by fibronectin, another adhesive protein found in circulation and tissues. As
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Cell Adhesion & Spreading
(Integrins, uPAR)

Blood Coagulation
(T-AT III complex, Heparin)

Fibrinolysis
(PAI-1, uPAR)

Vitronectin

Immune defense
(Components of Complement)

ECM Anchoring
(GAGs, Syndecan, Collagen)

Fig. 1-2. Vitronectin is linked to many biological functions. Vitronectin mediates
contacts that bridge cells to the surrounding ECM, and in a unique way serves to link
these cell-matrix associations with localized proteolytic cascades that are involved in
a diverse list of humoral defense mechanisms.
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mentioned before, vitronectin contains binding sites for both cell-surface receptors and
components of the ECM, and therefore represents a powerful bridging agent in the
association of cells with their surrounding microenvironment.
Vitronectin promotes cellular adhesion, spreading, and migration of a wide variety of
cell types, including fibroblasts, endothelial cells, megakaryocytes, platelets, and certain
tumor cell lines [60]. These different cells lines all can mediate attachment to tissues via
the presence of integrins on the cell surface. Integrins are a major group of versatile
receptors that serve in both adhesive and signaling functions. Integrins are composed of
non-related α- and β-subunits that are associated by non-covalent interactions that are
promoted by divalent cations. The integrin superfamily displays a wide functional
diversity, owed to the variable subunit composition of each receptor. Integrins known to
associate specifically with vitronectin include αVβ1, αVβ3, αVβ5, and GPIIbIIIa [30,6066], As mentioned before, binding of integrins to vitronectin is mediated mainly through
an RGD sequence located at the N-terminus of the protein. Growing evidence indicates
that there are certain signaling pathways associated with the binding of vitronectin to
several different integrins, which can alter protein expression and cellular behaviors like
migration and invasion.
By spanning the plasma membrane, integrins serve to connect the intracellular
cytoskeleton to the extracellular environment. In this way, integrins use mechanical
stimuli, such as adhesion to the ECM, to transduce information into biochemical signals
that can profoundly alter cellular processes link to adhesion, proliferation, migration,
invasion, and even detachment. Hapke et al. [67] recently reported that the interaction of
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vitronectin with αVβ3 alters the expression of the urokinase plasminogen activation
system in human ovarian cancer cells. This study demonstrated that vitronectin binding
to αVβ3 resulted in a down-regulation in the expression of uPA and uPA, while causing
an increase in PAI-1 levels by 4-fold. Another important finding demonstrates that αVβ3
binding to vitronectin can cause an increase in the production of the anti-apoptotic factor
Bcl-2, an event that correlated with protection from apoptosis [68]. Lastly, Tsou et al.
showed that vitronectin binding to both αVβ3 and αVβ5 on human microvascular
endothelial cells resulted in an increase in several growth factor receptors, including
FGFR and VEGFR.
Another way that vitronectin mediates cell adhesion is by interacting with the GPIlinked receptor, uPAR [60,69,70]. Vitronectin has been shown to bind uPAR on the
surface of endothelial cells, monocytes, and myeloid cells, and fibroblasts, promoting
their adhesion to the ECM . In fibrinolysis, uPAR serves to focus the proteolytic activity
of bound plasminogen activators at the leading edge of migrating cells. Attachment of
cells to vitronectin via uPAR has been shown to coordinate wound healing, tumor
migration, and invasiveness. As in other matrix proteins, such as fibronectin and
fibrinogen, vitronectin contains binding sites for both cell-surface receptors and ECM
molecules. Through interactions with glycosaminoglycans and collagen [47,71-76],
vitronectin can associate with the ECM and support an adhesive microenvironment for
cellular activities like adhesion and migration through integrin receptors and uPAR.
Discuss in depth the role of vitronectin as a integrating part of the ECM; evidences of
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what it can bind, that this binding is related to conformation changes in vitronectin, and
again state that the “activation” trigger is unknown.

Vitronectin Regulates Thrombosis and Fibrinolysis—Arguably, the most important
biological parter of vitronectin is the anti-fibrinolytic protein, PAI-1. PAI-1 is a serine
protease inhibitor (serpin) and serves as the main regulator of the plasminogen activators,
uPA and tPA, during tissue remodeling events like wound healing and cancer. uPA and
tPA are responsible for the cleavage of blood plasminogen into its active form, plasmin,
which is a non-specific protease that aggressively degrades protein matrices, including
fibrin clots associated with wounded tissue. Serpins represent a superfamily of inhibitors
that share a common structural organization and a common mechanism of inactivation of
their target enzymes. As shown in Figure 1-3, PAI-1 adopts a unique structure with
features that are pertinent to its inhibitory mechanism. The image on the left (panel A)
shows PAI-1 in its active conformation, with a common reactive center loop (RCL) that
protrudes outward from the main body of the protein which is made up of a β-sheet core.
In all inhibitory serpins, the RCL serves as a pseudosubstrate for the partner protease.
When tPA or uPA act on the RCL of PAI-1, a 1:1 stoichiometric complex is formed with
the rapid formation of a covalent bond between the protease active site (serine hydroxyl)
and the main-chain carbonyl at the P1 residue on the RCL of PAI-1. The covalent
complex of uPA/tPA and PAI-1 undergoes a dramatic conformation rearrangement
leading to loop insertion to the β-sheet core and irreversible inhibition.
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A

B

RCL

RCL
insertion
T1/2 = 90 min

Active PAI-1

Latent PAI-1

Fig. 1-3. Comparison of active and latent forms of PAI-1. Structure of active
PAI-1 solved for the stable variant 14-1B-PAI-1. The regions that undergo the
largest conformational shifts are indicated in dark gray. These include the reactive
center loop (RCL, residues 331-357), which moves from an exposed position as
“bait” for the target protease to a sequestered position at the central strand of the core
β-sheet. This structural reordering requires movement of the RCL around the Cterminal face of PAI-1 with an outward shifting of strands 1A, 2A, and 3A, as well as
a “hinging” motion by the small coil-turn-helix domain at the lower center of the
structure. [Reconstructed from Figure 1 of Biochemistry, Vol. 39, No.29 (2000)
page 8461 (add ref #)]
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PAI-1 is a unique serpin in that its active, inhibitory conformation (Fig. 1-3 panel A) is
relatively unstable and spontaneously converts to an inactive, latent form (panel B).
Under physiological conditions, human active PAI-1 has a half-life of ~90 minutes [77].
The conversion to latency by PAI-1 is characterized by insertion of the PAI-1 RCL into a
central β-sheet with the body of the protein [78]. As mentioned before, vitronectin
binding to PAI-1 restricts the sliding movement in the central β-sheet that facilitates the
conversion of PAI-1 to the inactive form. As such, binding of vitronectin causes a 2-4
fold increase in the half-life of active PAI-1 [77], making vitronectin an important cofactor in the regulation of plasminogen activation. Interestingly, vitronectin binding to
PAI-1 also endows the inhibitor with a new specificity for the clotting enzyme thrombin,
although the physiological significance of induced specificity of PAI-1 for thrombin is
not known.

Vitronectin Regulates the Immune Response of Complement—The humoral immune
response system in humans is supported by the complement system, whose activation via
proteolytic cascade mechanisms leads to the lytic destruction of antibody-opsonized
invasive cells or microorganisms. Steps leading to cellular lysis involve the interactions
of several complement components, including C5b, C6, C7, C8, and C9, that join
together to form a membrane attack complex [79]. These hydrophilic components form
complexes that are amphiphilic and insert into the membrane of attacked cells. In a final
step involving polymerization of component C9, a resulting lytic pore is formed.
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Vitronectin has been shown to interact with many of the complement components, as
well as the step-wise complexes that the component form, resulting in water-soluble
complexes that cannot insert into the cell membrane or are prevented from polymerizing
into an active lytic pore. The ability of vitronectin to inhibit complement complexes
from forming most likely reflects a protective function for vitronectin, which serves to
protect from innocent bystander cell lysis of host tissue.

Vitronectin and Embryonic Development—Through its ability to regulate such a
diverse number of functional pathways, vitronectin serves as an integral part of several
normal and pathological processes. The broad functional activities of vitronectin,
especially those related to cell/matrix adhesion and vascular hemostasis, suggests that the
protein may play a critical role in mammalian development. Several studies have linked
vitronectin to the developing nervous system at early stages of mouse organogenesis.
Studies carried out by Martinez-Morales and Rodreiguez-Tebar [80,81] tested this
hypothesis by evaluating the role of vitronectin in the developing chick retina. Ventral
neural tube extracts from chick embryos, vitronectin promoted the generation of motor
neurons. Neugebauer [82] confirmed these results promoted neurite outgrowth during
retinal development, and that this activity was dependent on the interaction of vitronectin
with the cell-surface integrin αVβ1.
Pons [83] demonstrated the activity of vitronectin in the developing cerebellum and
found that vitronectin regulates neuronal proliferation and differentiation, and that this
regulation was dependent on Sonic hedgehog and that vitronectin stimulated the
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phosphorylation of cyclic-AMP reponse element binding protein (CREB). This event
was also shown to be integrin-dependent.. Involvment in bone development [84].
Sumida [85] showed that vitronectin was important during heart development, where the
protein was proposed to regulate endocardial cell migration in the developing chick heart.
Isahara [86]demonstrated that during development vitronectin regulated interactions
between developing peripheral nerves and blood vessels. In these studies, they
demonstrated that vitronectin promoted neutrite outgrowth by dorsal root ganglion cells
onto vascular endothelial cells. Interestingly, mice deficient in vitronectin demonstrate
normal development, fertility, and survival [87]. These studies do not, however, negate
the above findings or the probability of vitronectin’s role in development, but most likely
indicate that the functions of vitronectin may partially overlap that of other adhesive
matrix components that may compensate for the absence of vitronectin.

Vitronectin in Wound Healing and Disease—The process of coagulation is a
complex mechanism that involves many components that come together in a highly
regulated manner to prevent the excessive loss of blood and initiate tissue repair.
Coagulation occurs through an accelerated proteolytic cascade that ultimately leads to the
conversion of fibrinogen into its insoluble counterpart, fibrin. The enzyme responsible
for the catalytic conversion of fibrinogen into fibrin is the serine protease, thrombin.
Following conversion, fibrin readily associates with platelets and ECM at the site of
injury, forming a primary hemostatic plug. In this scenario, thrombin is tightly regulated
by the protease inhibitor anti-thrombin III (AT III), which forms a stable complex with
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thrombin. Although AT III inhibition of thrombin is irreversible, the rate of inhibition is
slow. However, heparin, and other glycosaminoglycans found in the vascular space,
form interactions with AT III that induce conformational changes leading to enhanced
reactivity towards thrombin. In doing so, heparin serves as a powerful anti-coagulating
agent, causing a down-regulation in the formation of insoluble fibrin.
Vitronectin can control the coagulation process by directly interacting with heparin.
This interaction “neutralizes” heparin by impeding its binding to either thrombin and/or
AT III. Thrombin remains active and clot formation is favored, and in this way
vitronectin serves as a pro-coagulating factor during wound response. Interestingly,
vitronectin directly interacts with the thrombin-AT III complex, but the exact functional
significance of this event is unknown. Studies have shown that vitronectin/thrombin-AT
III complexes are rapidly cleared from circulation, suggesting a potential role in tissue
deposition and remodeling [88,89]. The diverse functional capabilities of vitronectin,
especially those related to cell adhesion and pericellular proteolysis, make the protein a
perfect candidate for aiding in the body’s response to pathological events like wounding
and disease.

Distribution of Vitronectin in Circulation and Tissues
Vitronectin is present predominantly as a monomer in circulation at a concentration of
0.25-0.45 mg/ml (~4-7 micromolar) [13], and constitutes approximately 1 percent of total
plasma proteins. Although the hepatocyte is the major vitronectin-producing cell type, a
limited number of other cells, including blood-derived (cultured) monocytes,
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macrophages, and megakaryocytes, have been reported to synthesize and secrete
vitronectin [13,90]. However, drastic reductions in plasma levels of vitronectin are
observed in patients with severe liver failure, indicating that the liver is the major source
of circulatory vitronectin.
A second circulatory pool of vitronectin is found with platelets, where it exists in
releasable form within α-granules. Upon activation during thrombosis, platelets rapidly
release vitronectin such that their ability to adhere to the surrounding tissue is enhanced.
Interestingly, vitronectin found within platelets is in a multimeric form and is
immunologically similar to the form of vitronectin adopted following denaturation.
In addition to its presence in circulation, vitronectin is also found associated with the
ECM of tissues. Although immunohistochemical studies demonstrate that vitronectin is
normally absent from most tissues, the protein becomes deposited at sites of injury and
disease. Examples of this (see Table 1-I) include vitronectin deposition in
diseased/injured tissues of brain [91], skin [92-94], kidney [95-103], liver [102,104-107],
vascular system [108-111], lymph [112], ovary [113], breast [107,114,115], bone [112],
colon [114], and pancreas [116]. In these various tissues, vitronectin is assumed to take
on an adhesive role and, like the platelet form, is conformationally distinct from the
circulating (monomeric) form of the protein. The absence of detectable vitronectin
biosynthesis in tissues suggest that there must be a specific mechanism(s) that mediates
the uptake of circulating vitronectin into tissues.
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Table 1-I. Deposition of vitronectin in injured/disease tissue.
Tissue type;
Injured/Diseased Localization Pattern

Co-Localized
Binding Partners

Refs.

Brain
Cerebral amyloid plaques in Alzheimer’s Disease

αV Integrin Subunit

Eikelenboom et al. 1994 (91)

Skin
Solar elastosis and dermal amyloid deposits in certain skin diseases
Lesions In discoid lupus erythematosus and dermatitis herpetifomris
Lesions in lichen planus pemphigoides

N/A
Complement
Complement

Dahlback et al. 1988 (92)
Dahlback et al. 1989 (93)
Hintner et al. 1990 (94)

Lesions in glomerulonephritis

PAI-1, tPA
Complement, αVβ3
Complement

Lesions in renal infarction/ischemia
Sclerotic lesions in childhood IgA nephropathy
Amyloid deposits in amyloid A and light chain type amyloidosis
Immunoglobulin glomeruli deposits
Lesions in diabetic nephropathy and arterionephrosclerosis

Complement
Complement
N/A
Complement
Complement

Nakamura et al. 1996 (96)
Ogawa et al. 1994 (97)
Murphy et al. 1989 (99)
Okado et al. 1993 (98)
Vakeva et al. 1995 (100)
Takahashi et al. 1995 (101)
Dahlback et al. 1987 (95)
Inuzuka et al. 1997 (102)
Falk et al. 1987 (103)

Kidney
Glomerular deposits in membranous nephropathy

Liver
Areas of chronic and mature fibrosis in cirrhosis
Hepatic fibrosis in liver disease
Lesions in chronic hepatitis and cirrhosis

N/A
PAI-1
N/A
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Koukoulis et al. 2001 (104)
Inuzuka et al. 1997 (105)
Kobayashi et al. 1994 (106)
Jaskiewicze et al. 1993 (107)

Table 1-I. Continued.
Tissue type;
Injured/Diseased Localization Pattern

Co-Localized
Binding Partners

Vascular
Heart lesions in myocardial infarction
Fibrous tissue and plaques in atherosclerosis

Complement
Complement

Neointimal atherosclerotic arteries

Thrombin, PAI-1

Vakeva et al. 1993 (108)
Niculescu et al. 1987 (109)
Van Akon et al. 1997 (110)
Stoop et al. 2000 (111)

Lymph
Fibrotic lymph nodes in Hodgkin’s disease/metastatic carcinomas

N/A

Reilly et al. 1988 (112)

Ovary
Differentiated ovarian carcinomas

αVβ3

Carreiras et al. 1996 (113)

Breast
Infiltrating duct carcinomas

N/A

Loridon-Rosa et al. !988(114)
Aaboe et al. 2003 (115)
Jaskiewicze et al. 1993 (107)

Bone
Myelofibrotic bone marrow

N/A

Reilly et al. 1988 (112)

Colon
Colonic adenocarcinomas

N/A

Loridon-Rosa et al.1988(114)

Pancreas
Pancreatic carcinomas

αV Integrin Subunit

Linder et al. 2001 (116)
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Refs.

Statement of Scientific Problem—The mechanism that causes the conversion of
circulating (monomeric) vitronectin to a tissue-associated form is currently unknown. In
addition, the potential ramifications of the association with vitronectin are poorly
understood. Considering pathological states such as injury, inflammation, and cancer,
these questions surrounding vitronectin are important to explore.

Conformational Flexibility of Vitronectin:
Testing the Mechanisms of Activation
Early studies demonstrated that human plasma contains two structurally and
functionally distinct forms of vitronectin. Physical characterization of the two forms
demonstrated that the least abundant form (representing less that 2% of the total
vitronectin in plasma) is in a higher-order form, consisting of 6.5 S aggregates with a
Stokes radius of 5.6 nm, compared to the most abundant form isolated from plasma,
which is a 4.2 S monomer with a Stokes radius of 3.9 nm. Functional assays
demonstrated that only the 6.5 S multimeric form of vitronectin associated with heparin,
and this form also diplayed increased reactivity (as compared to monomeric vitronectin)
towards anti-vitronectin antibodies. This studies indicated that vitronectin can exist in at
least two distinct forms that display important differences in conformation and function,
but that the major form found in circulation is monomeric and “silent” in certain binding
activities.
It was later discovered that denaturation of vitronectin with chaotropic agents, heat
treatment, and acidification greatly increased its reactivity with heparin. A number of
conformationally sensitive antibodies and ligands of vitronectin, including collagen,
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glycosaminglycans, β-endorphin, PAI-1, integrins, and the urokinase/uPAR receptor,
were all shown to interact preferentially with the conformationally altered, denatured
form of vitronectin [90]. Research from this laboratory demonstrated that denaturation of
vitronectin results in the formation of homo-multimers that display enhanced binding to
specific ligands, such as heparin, through the generation of multivalent interactions that
arise following an induced “clustering” of individual low-affinity binding sites [117,118].
Finally, complex formation of vitronectin with several ligands, including PAI-1,
thrombin-antithrombin III, and complement C5b-C9, also induces conformational
changes in vitronectin that are similar to those induced by artificial means [119-121].
These changes are likewise associated with the multimerization of vitronectin into
multivalent complexes that diplay both structural and functional divergence from the
non-bound, monomeric form. What is the biological significance of vitronectin
multimerization? Is ligand-induced multimerization a physiological mechanism
that regulates the localization and functions of vitronectin? Referring to Figure 1-4,
there is an artificial model and a physiological model, which we adopt for studying the
potential mechanism for the activation of vitronectin. Considering the lability of
vitronectin, a plausible explanation for how the protein becomes deposited into the ECM
of tissues is through a ligand-induced mechanism. Binding of vitronectin to biological
co-factors like PAI-1 and complement complexes would lead to formation of higherorder complexes that can readily associate with the ECM and nearby or migrating cells.
Supporting this idea is the observed colocalization of vitronectin with ligands like PAI-1
and complement in areas of fibrosis, necrosis, and inflammation [102,111,122-126].
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A. Artificial model of vitronectin “activation”
Chemical daturation
Heat denaturation
Acidification

►Multimerization
►Altered antibody recognition
►Enhanced heparin binding
►Enhanced cell/matrix binding

B. Physiological model
Tissue injury/Inflammation
Cancer
Complement

PAI-1
T-AT
Complement factors

►Multimerization
►Recruitment to tissues as a pro-adhesive form
►Facilitate cell adhesion/migration
►Regulate matrix remodeling via proteolytic
cascades

Fig. 1-4.
Models for evaluating the structural/functional activation of
vitronectin. Much information regarding vitronectin has been gained evaluating a
more non-physiological model (Panel A). Focus in now being made on more
physiolgically possible mechanisms leading to vitronectin activation (Panel B).
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Working Hypothesis—PAI-1-binding to vitronectin induces the formation of higherorder complexes that display altered adhesive properties distinct from the circulating
(monomeric) form of vitronectin. These altered adhesive properties arise from the
induction of multivalent binding sites for both cell surfaces and components of the ECM.
Formation of vitronectin/PAI-1 complexes follows a step-wise assembly process that is
dependent on protein concentration and time, ultimately leading to an increased
accumulation of vitronectin at the cell-matrix interface
PAI-1 represents a physiological cofactor for the conversion of vitronectin from a
circulating, monomeric form to a matrix-associated, “activated” form. PAI-1-binding
to vitronectin induces the formation of higher-order complexes that display altered
adhesive properties distinct from the circulating (monomeric) form of vitronectin.
These altered adhesive properties arise from the formation of multivalent binding sites
for both cell surfaces and components of the ECM. Formation of vitronectin/PAI-1
complexes follows a step-wise assembly process that is dependent on protein
concentration and time, ultimately leading to an increased accumulation of vitronectin
at the cell-matrix interface.

Research Aims—To address the working hypothesis stated above, the following
research objectives were designed and carried out. A schematic in Figure 1-5 illustrates
the overall system of studies to be carried out and the questions addressed.
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Assembly Process
(Chaps. 2 & 4)

VN

+

?

?

Higher-order
Complexes
Formed
(Chaps. 2 & 4)

PAI-1
4:2
PAI-1:VN
Complex

?

Functional effects
(Chaps. 2 & 3)

Fig. 1-5. Schematic representing the working model to be investigated. Both
biological and biophysical studies are designed to evaluate the mechanism and
functional consequences of PAI-1-induced multimerization of vitronecctin.
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Aim 1: To test the effects of PAI-1-induced multimerization on the interaction of
vitronectin with cell-surface integrins and components of the ECM.
The set of studies described in Chapter 2 were designed to carefully monitor the
formation of higher-order vitronectin/PAI-1 complexes and correlate these findings with
binding studies using cells and purified components of both cell surface receptors and the
ECM. To follow complex formation, mixtures of vitronectin and PAI-1 were analyzed
by size-exclusion HPLC under various conditions. In conjunction, complexes were
tested for their ability to associate with cell surfaces and extracellular matrices in a solidphase platform. These experiments demonstrated a direct correlation between the
formation of higher-order vitronectin/PAI-1 complexes and enhanced binding of
vitronectin to both cell surfaces and the ECM. These findings support a role of PAI-1induced multimerization in the deposition of vitronectin at the cell-matrix interface and
provide a plausible mechanism through which circulating vitronectin is converted to a
tissue-associated form.

Aim 2: To evaluate the effects of PAI-1-induced multimerization of vitronectin in a
living cell system using human fibroblasts.
Studies carried out for Objective 2 (described in Chapter 3) were designed to
complement the solid-phase binding assays performed for Objective 1. By utilizing a
living system, we gain more physiological support regarding our model that
vitronectin/PAI-1 complexes display adhesive properties that develop through the process
of ligand-induced multimerization of vitronectin. The results presented in this chapter
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provide new evidence that PAI-1/vitronectin complexes display enhanced interactions
with human fibroblast monolayers, an event that would be significant during homeostatic
responses such as wound healing and tissue remodeling. In these studies,
vitronectin/PAI-1 complexes displayed enhanced association with cell monolayers and
cell surface receptors, leading to a greater degree of endocytosis and lysosomal
degradation of vitronectin compared to the native vitronectin. These findings were
monitored using both biochemical assays and immunofluorescence microscopy. Binding
of vitronectin/PAI-1 complexes to fibroblast monolayers is shown to be dependent on the
presence of sulfated glycosaminolglycans and uptake to be partially dependent on cellular
integrins. These results provide strong evidence in a living cell system that PAI-1induced multimerization can regulate the incorporation of vitronectin into an adhesive
matrix protein.

Aim 3: To evaluate the mechanism of assembly of higher-order vitronectin/PAI-1
complexes.
In the studies presented in Chapter 4, we characterize the biochemical mechanism
involved in the assembly of higher-order vitronectin/PAI-1 complexes that become
adhesive in nature. This characterization ultimately will address the following questions:
What types of higher-order complexes form as a result of the vitronectin/PAI-1
interaction? What is the order of steps leading to the assembly of higher-order
complexes? What are the kinetic and binding parameters associated each step? What is
the concentration dependence of PAI-1 on complex formation? What molar

31

stoichometries for vitronectin and PAI-1 exist for the different species of complexes
formed?
To begin addressing these questions, fluorescence- and hydrodynamics-based
experiments were carried out to follow the formation of vitronectin/PAI-1 complexes.
Equilibrium binding assays, using a fluorescently-tagged PAI-1, demonstrate that binding
of vitronectin to PAI-1 occurs in an allosteric manner, through which two separate PAI-1binding sites become occupied. Sedimentation velocity experiments were used to
observe the types of vitronectin/PAI-1 that build off the 1:2 and 2:4 (vitronectin:PAI-1)
complexes that are reported to form [127]. These studies were also used to test the
effects of time, ionic strength, and protein concentration on the assembly of higher-order
complexes. In short, the results described in this chapter provide valuable information
regarding the step-wise formation of vitronectin/PAI-1 complexes, and give further
insight into how complex formation between these two proteins may support adhesive
processes during wound healing and tumor metastasis.
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CHAPTER 2
PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 PROMOTES
THE SELF-ASSOCIATION OF VITRONECTIN INTO COMPLEXES
EXHIBITING ALTERED INCORPORATION INTO THE
EXTRACELLULAR MATRIX*

*This chapter is a revised version of a manuscript under the same title published in the
Journal of Biological Chemistry in 2001 by Kenneth H. Minor and Cynthia B. Peterson
[128]:
Minor, K. H. and Peterson, C. B. Plasminogen activator inhibitor type 1 promotes the
self-association of vitronectin into complexes exhibiting altered incorporation into the
extracellular matrix. Journal of Biological Chemistry 277 (12): 10337-10345.
My contributions to this paper include: (1) aiding in the development and design of
experimental goals and procedures, (2) performing all experiments and collections of
data, (3) analyzing collected data, (4) designing how the results were illustrated, and (5)
writing and publication of the work in collaboration with my mentor Dr. Cynthia
Peterson.

Introduction
As discussed in the opening chapter, the diverse functionality of vitronectin arises from
its ability to interact with many biological ligands, including the thrombin-antithrombin
complex, PAI-1, and components of complement [13,40,88]. In addition to these
functions, vitronectin is conformationally labile and exists both in circulation and the
ECM of tissues. During pathological events such as wounding and disease, we propose
that circulating vitronectin undergoes structural changes that cause the protein to
associate with cell surfaces and the ECM of affected tissues. The mechanism that leads
to the transition, or “activation”, of vitronectin from a circulating-form to a tissueassociated form remains unclear. The underlying hypothesis of this dissertation states
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that interactions of vitronectin with certain biological ligands, here PAI-1, result in the
formation of multimeric complexes that have a propensity to associate with cell surfaces
and the ECM.
PAI-1 binding has been linked to conformational changes in vitronectin, which result in
the formation of multimeric structures with binding properties different from that of
monomeric vitronectin [119,127]. Multimeric forms of vitronectin have been shown to
readily associate with both cell surface receptors and ECM components
[47,61,118,119,129-132], indicating that multimerization in vivo might be the key step
leading to the conversion of vitronectin to a matrix-associated form. Importantly, both
vitronectin and PAI-1 have been detected co-locally with tissues undergoing wound
healing or tumor metastasis [102,111,123-126], suggesting that the two proteins serve as
co-factors in matrix deposition and remodeling.
The following studies were designed to monitor the formation of higher-order
vitronectin-PAI-1 complexes and correlate these findings with binding studies using cells
and purified components from both cell surfaces and the ECM. To follow complex
formation, mixtures of vitronectin and PAI-1 were analyzed by size-exclusion HPLC
under various conditions. In conjunction, complexes were tested for their ability to
associate with cell surfaces and extracellular matrices in a solid-phase platform. Our
findings support a role of PAI-1-induced multimerization in the deposition of vitronectin
at the cell-matrix interface.
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Materials and Methods
Proteins and Antibodies—Native vitronectin was purified from human blood plasma
using a modified protocol of the method developed by Dahlback and Podack [133,134].
Human GPIIbIIIa was obtained from Enzyme Research Laboratories. Human αVβ3 came
from Calbiochem. Recombinant human PAI-1 (wild-type) and tPA were obtained from
Molecular Innovations. Latent PAI-1 was either prepared by 24-hour incubation of wildtype PAI-1 at 37 ºC, or it was purchased from Molecular Innovations. Human ECM and
Matrigel were purchased from Becton Dickinson. Polyclonal antibodies against
vitronectin were generated in rabbits by contract with Rockland Laboratories. A
monoclonal antibody specific for PAI-1 was a kind gift of Dr. Tom Podor. Peroxidaselabeled secondary antibodies (anti-rabbit and anti-mouse) were obtained from Vector
Laboratories. Protein standards used for HPLC came from Amersham Biosciences, Inc.
Native vitronectin was phosphorylated using [γ-32P]ATP (Amersham Biosciences, Inc.)
and protein kinase A (catalytic subunit, product of Sigma). Unincorporated radiolabel
was removed by a desalting centrifugation step using Bio-Spin 30 columns. Specific
radioactivity was determined directly by quantifying vitronectin in a BCA assay (Pierce)
and measuring radioactivity in a Beckman LS3801 Scintillation Counter. Specific
radioactivity was 100,000 cpm/pmol of vitronectin.

Size Exclusion HPLC—Chromatography of vitronectin/PAI-1 mixtures was carried
our using a Phenomenex Biosep SEC-S3000 (300 x 7.8 mm) column attached to a
Hewlett-Packard 1100 series HPLC system. PBS containing 0.005% (w/v) sodium azide
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was used for the reaction and isocratic mobile phase. Equimolar concentrations of
vitronectin and PAI-1 were mixed and incubated for various times at 37 ºC. In some
experiments, an equimolar amount of tPA was added at the end of the incubation period
to inactivate PAI-1 and dissociate it from vitronectin. On occasion, NBD-S119C PAI-1
was used to explicitly monitor the absorbance of NBD at 494 nm as a probe for PAI-1.
Samples (50 µl) were injected onto the pre-equilibrated size-exclusion column and
chromatographed at room temperature at a flow rate of 1 or 0.5 ml/min. Absorbance was
detected directly in the flow cell at 280 nm or 494 nm.

SDS-PAGE and Western Blotting—Samples (100 µl) were collected from HPLC runs
and analyzed by PAGE on 10% polyacrylamide SDS gels. Proteins were transferred to
nitrocellulose filters using a Semi-Dry Blotter (BioRad) in transfer buffer (0.35 M
glycine, 25 mM Tris containing 20% (v/v) methanol). Filters were blocked for nonspecific binding using 10% (w/v) nonfat dry milk at room temperature for 1 hour.
Membranes were then washed three times after this and subsequent incubation steps with
PBS containing 0.05% (v/v) Tween-20. Immunoblotting was performed to detect
vitronectin and PAI-1 simultaneously by incubating the filters with a 1:2,500 dilution of
polyclonal anti-vitronectin rabbit serum and a monoclonal antibody raised against PAI-1.
Antibodies were diluted in a 2.0% (w/v) solution of nonfat dry milk in PBS. Blots were
then probed using a 1:1,000 dilution of HRP-linked goat anti-rabbit and rabbit anti-mouse
antibodies. Immunostained protein bands were visualized by developing in a freshly
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prepared solution of 30 ml of PBS containing 50 mg/ml 4-chloronapthol and a 1:3,000
dilution of 30% (v/v) hydrogen peroxide.

Fluorescence Measurements—Changes in the fluorescence emission of NBD-S119CPAI-1 were measured using a PerkinElmer LS50B luminescence spectrophotometer with
an extinction wavelength of 480 nm and emission wavelength of 525 nm. Excitation and
emission slits were set at 4 and 7 mm, respectively. Solutions of NBD-PAI-1 (200nM) in
HEPES buffer (100 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1% [w/v] polyethylene
glycol-8000, pH 7.4) were titrated with small aliquots of vitronectin to a final
concentration of 550 nM. Samples were mixed in a total volume of 2.0 ml in acrylic
cuvettes (Sarstedt) that were pre-treated with a 1.0% (w/v) solution of polyethylene
glycol-20,000. Titrations were performed in triplicate. All data were mathematically
corrected for dilution effects. Change in emission was calculated using the equation (FFo)/Fo, where F is the emission intensity and Fo is the starting emission intensity of NBDPAI-1 in the absence of vitronectin. Emission scans were performed over a wavelength
range of 500-600 nm using an excitation wavelength of 480 nm. Measurements were
plotted as a function of titrant concentration using the graphing KaleidaGraph (Synergy
Software). Data were fit to the Hill equation,
(Eq.3-1)

where S is the total titrant concentration, K0.5 corresponds to the titrant concentration at
half-maximal saturation, and n is the Hill coefficient.
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Cell Binding Assays—Rabbit smooth muscle cells (gift from Dr. Dan Lawrence,
American Red Cross) were grown to near confluence in tissue culture dishes in
Dulbecco’s modified Eagle’s medium (DMEM). Cells were harvested by trypsinization
and subsequently incubated in DMEM containing 32P-labeled vitronectin with or without
PAI-1. Control cell binding experiments were also carried out using latent PAI-1.
Mixtures were incubated at 37 ºC for 1 hour. Following incubation, cells were
centrifuged at 12,000 x g and resulting pellets were washed three times with PBS.
Washed cell pellets were placed into a liquid scintillation mixture and measured for
radioactivity in a Beckman LS3801 scintillation counter.

Matrix Binding Assays—96-well ELISA plates (polypropylene or polystyrene, CoStar)
were coated with ECM (500 ng/well) or Matrigel (2.5 µg/well) in PBS. Wells were
washed three times with PBS and then blocked with 3.5% (w/v) BSA for 1 hour at 37 ºC.
Vitronectin and PAI-1 were mixed in variable ratios in PBS containing 0.2% BSA and
0.1% (v/v) Tween-20 (to prevent nonspecific binding), and samples were incubated for
various times at 37 ºC. Following washing with buffer containing BSA and Tween,
vitronectin/PAI-1 mixtures (100 µl) were added and incubated at 37 ºC for 1 hour.
Following incubations, mixtures were removed , wells washed, and bound vitronectin
was detected by two different methods. For ECM binding assays, detection was done
using a polyclonal anti-vitronectin IgG and a peroxidase-conjugated anti-rabbit IgG.
Plates were developed with a 0.2 mg/ml solution of ABTS in 50 mM sodium citrate, pH
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5.5, containing a 1:2,000 dilution of 30% hydrogen peroxide. Detection was carried out
in a Wallac Victor2 ELISA plate reader at a wavelength of 405 nm. For the Matrigel
binding assays, 32P-labeled vitronectin was used and bound protein was detected by
scintillation counting. Nonspecific binding was monitored in all experiments and found
to be minimal. Effects of nonspecific binding were subtracted from reported results.
Assays described here were also performed to test the effects of ionic strength and tPAmediated release of PAI-1, using equimolar concentrations of tPA and PAI-1.

Integrin Binding Assays—ELISA plates were coated with 250 ng of GPIIbIIIa or αVβ3
in Integrin-Binding Buffer (IBB, 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1
mM CaCl2). Wells were washed three times with IBB and then blocked with 3.5% (w/v)
BSA for 1 hour at 37 ºC. Equimolar or 1:2 (vitronectin:PAI-1) mixtures were incubated
in IBB containing 0.2% BSA and 0.1% (v/v) Tween-20 for various times at 37 ºC.
Following washing with IBB containing BSA and Tween, blocked wells were layered
with vitronectin/PAI-1 mixures and incubated at 37 ºC for 1 hour. Immunochemical
detection of vitronectin was performed as described for the ECM binding assays. Assays
were also performed to test the effects of metals, ionic strength, and tPA-mediated release
of PAI-1.

Results
Size Exclusion HPLC Was Used to Monitor the Formation of Large Complexes
Resulting from PAI-1 Binding to Vitronectin—For the purposes of the experiments
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described in this chapter, namely to investigate the effects of PAI-1-induced
multimerization of vitronectin on cell-matrix binding, an HPLC method of size-exclusion
chromatography was employed to monitor the formation of multimers. Figure 2-1 shows
chromatograms of equimolar mixtures of vitronectin and PAI-1 that were incubated for
various times. Separation immediately following mixing demonstrated the fast formation
of very large complexes (elution time = 6 minutes). From 1 to 4 hours, significant
amounts of the high molecular weight complexes accumulated. Analysis at long times
(up to 36 hours) demonstrated that high molecular weight forms of vitronectin persisted,
long after the disassociation of PAI-1 from the complex upon its conversion to a latent
form.
In the HPLC experiments, NBD-S119C PAI-1 provided a chromophore to directly
determine whether PAI-1 was an integral part of the high molecular complexes that form.
As shown in Figure 2-2 (panel A), the elution profile at 494 nm (the extinction maximum
for NBD) confirms that PAI-1 is present in the high molecular weight complexes formed
after 1 hour. Furthermore, SDS-PAGE and Western blotting (panel B) confirmed that
these large complexes contained both vitronectin and PAI-1. The same approach
indicated that the high molecular weight species observed at long times (e.g. 36 hours)
comprised oligomeric forms of vitronectin without associated PAI-1. As a control, latent
PAI-1 did not cause the formation of large complexes with vitronectin. These results are
in agreement with findings from earlier reports investigating the interaction between
vitronectin and PAI-1 [119,127].
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Fig. 2-1. Size-exclusion HPLC evaluation of PAI-1-induced multimerization of
vitronectin. Equimolar concentrations of vitronectin and PAI-1 were mixed and
injected onto a Phenomenex size-exclusion column and chromatographed at a flow
rate of 1 ml/min. Reactions were carried out in PBS over several time points up to 36
hours. Samples were monitored at an absorbance of 280 nm. Large complexes
eluted from the column at the void volume elution time (time = 6 min). Peak elution
times measured for free vitronectin and free PAI-1 are 9.2 and 10.4 minutes,
respectively.
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Fig. 2-2. PAI-1 is detected in high molecular weight vitronectin complexes.
Panel A depicts HPLC chromatograms for free NBD-S119C-PAI-1 (dashed line) and
the labeled PAI-1 in complex with vitronectin (solid line) eluting from the sizeexclusion column at a flow rate of 1 ml/min. Detection at 494 nm is specific for the
NBD chromophore. Note the presence of PAI-1 in complexes that elute at the void
volume (time = 6 minutes). Panel B shows SDS-PAGE and Western blotting to
confirm the presence of PAI-1 in the early eluting peaks fom the HPLC column.
Small volume (100 µl) fractions were collected at the elution times indicated by the
bar in panel A. These samples were run on a 10% polyacrylamide gel and transferred
to nitrocellulose for Western blotting analysis using anti-vitronectin and anti-PAI-1
antibodies concurrently. The far left lane on the gel, labeled Control Proteins,
contains purified vitronectin and PAI-1 that were combined in equal concentrations,
mixed with SDS-PAGE loading dye, and boiled for loading and electrophoresis.
Also shown in the far right lane are prestained molecular size standards.
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The information obtained from this HPLC gel filtration approach was instructive for the
remainder of the study described here. By monitoring the formation of complexes
between vitronectin and PAI-1 over time, we could correlate this information with effects
of PAI-1-induced multimerization on the adhesive properties of vitronectin. We were
especially interested in functions relative to matrix and/or cellular interactions.

PAI-1 Effects on Vitronectin Enhance Its Interaction with Extracellular Matrices—
Research from this laboratory [118], which demonstrates the positive effect of increased
valency (upon vitronectin multimerization) on the binding of vitronectin to heparin, raises
the possibility that PAI-1-induced oligomerization of vitronectin may also enhance the
binding of the protein to other ligands. Of particular interest is the association of
vitronectin and its complexes with the ECM, which will be enhanced by interactions with
the multivalent substrates in the matrix and which may be mediated by heparin-like
glycosaminoglycans. The ability of vitronectin to interact with both integrins and matrix
proteins places vitronectin at the boundary of cell-matrix interactions and activities.
Results presented in Figure 2-3 address this idea by demonstrating that vitronectin, when
incubated with PAI-1, shows increased binding to matrix-coated ELISA plates. The
enhanced binding of vitronectin upon incubation with PAI-1 was demonstrated using two
commercially available matrices, human ECM and Matrigel. Binding of complexes is
observed with both types of matrix and is detected using either immunochemical (panel
A) or radiological (panel B) detection, indicating a specific effect of PAI-1 on matrix

incorporation of vitronectin. These findings support a model in which PAI-1 promotes
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Fig. 2-3. Complexes of vitronectin and PAI-1 associate with the ECM. The
effects of PAI-1 binding on the adhesive properties of vitronectin were measured
using human ECM-coated ELISA plates (panel A) or Matrigel-coated plates (panel
B) as described in Material and Methods. Equimolar concentrations of vitronectin
and active PAI-1 were mixed and incubated for 1 hour prior to addition to matrixcoated wells.
Binding of varying concentrations of vitronectin (○) or
vitronectin/PAI-1 complexes (●) was detected using a polyclonal antibody against
vitronectin (panel A) or by scintillation counting (panel B). Error bars represent
standard errors.
44

the formation of vitronectin oligomers that display enhanced affinity for components that
constitute the ECM.
Although equimolar mixtures of vitronectin and PAI-1 exhibited enhanced association
with the ECM, as shown in Figure 2-3, we considered whether non-stoichiometric
mixtures of the two proteins would vary in matrix-binding behavior. This experiment
was initiated in light of published results from this laboratory that demonstrate the
association of vitronectin and PAI-1 into complexes with a 2:4 (vitronectin:PAI-1)
stoichiometry [127]. Thus, the concentration of vitronectin was fixed in the ECMbinding assays, whereas the concentration of PAI-1 was varied from less than
stoichiometric to a 4-fold excess relative to vitronectin. As shown in Figure 2-4, matrix
binding is dependent on the amount of PAI-1 present, saturating at a higher value for
relative binding than that observed for the 1:1 ratio kept constant in Figure 2-3. For this
reason, subsequent ECM-binding experiments were performed using a 2:1 ratio of PAI1:vitronectin, and these results show a greater enhancement in ECM binding than the
titrations shown in Figure 2-3. Latent PAI-1, tested over a wide range in concentrations,
had no effect on matrix binding by vitronectin.

The Time Course of PAI-1-Induced Multimerization of Vitronectin Parallels
Enhanced Association with the ECM—To correlate the observed effects of PAI-1
binding on vitronectin adhesive functions and the formation of large multimeric
complexes as a result of this interaction, these properties were carefully monitored over
time. Mixtures of vitronectin and PAI-1 were incubated for various times and then added
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Fig. 2-4. Vitronectin deposition into the ECM is dependent on PAI-1 binding.
Enhanced binding of vitronectin to the ECM was shown to vary with the amount of
PAI-1 in a saturable fashion using ECM-coated ELISA plates as described in
Materials and Methods. Increasing concentrations of active (▲) or latent (○) PAI-1
were mixed with a fixed concentration (20 nM) of vitronectin and incubated for 1
hour prior to addition to ECM-coated wells. Binding of the complexes to the matrix
is detected using a polyclonal antibody to vitronectin and a peroxidase-labeled
secondary antibody acting on ABTS. Product in the ELISA is detected by
absorbance at 405 nm. Results are expressed as the increase in binding relative to
the binding of vitronectin in the absence of PAI-1. Error bars represent standard
errors.
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to ECM-coated ELISA plates. Figure 2-5 (panel A) demonstrates the significant increase
in the amount of vitronectin bound to matrix when PAI-1 is added versus native
vitronectin alone. Strikingly, this increase in matrix deposition persists at long times
after which PAI-1 is no longer present in the large complexes. These results indicate that
PAI-1 binding causes a consistent enhancement of the adhesive form of vitronectin in a
temporal pattern similar to that of complex formation and vitronectin multimerization
observed in the HPLC time course described above.
To explicitly test whether PAI-1 is required as a component in the higher-order
complexes for the enhancement in binding to the matrix, tPA was added to the incubation
mixtures at timed intervals. This serine protease plays an important role in fibrinolysis,
where it directly converts plasminogen into the proteolytically-active plasmin. Plasmin is
important in breaking down fibrin clots and extracelluar remodeling. TPA attacks the
pseudo-substrate RCL on PAI-1, and inhibition occurs as PAI-1 forms a stable acylcomplex. It has been shown that when tPA acts on PAI-1 bound to vitronectin, the
vitronectin/PAI-1 interaction is disrupted and the tPA/PAI-1 complex is irreversibly
released [Lawrence, 1997 #174]. Dissociation of the vitronectin/PAI-1 complex by
adding tPA at early times (~1 hour) diminishes binding to the matrix, as shown in Figure
2-5 (panel A). Note that the binding observed is nevertheless enhanced relative to the
binding of monomeric vitronectin. Indeed, analysis by HPLC gel filtration (Figure 2-5
panel B) demonstrated that by 1 hour, a stable multimeric form of vitronectin that more

readily associates with the matrix is present, and that it persists even after tPA-mediated
release of PAI-1. The fact that tPA treatment reduces the amount of complexes observed
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Fig. 2-5. Evaluation of the effects of multimerization of vitronectin on binding
to the ECM using tPA to neutralize PAI-1. Panel A, samples of vitronectin with or
without active or latent PAI-1 were incubated for various times at 37 ºC and then
tested for binding to ECM-coated ELISA plates as described in Materials and
Methods. Results are expressed relative to the observed binding of free monomeric
vitronectin to the ECM, normalized to a value of 1. The solid bar represents the
binding of monomeric vitronectin to the plates, a value that remains unchanged over
the time course of the experiment.
Open bars represent the binding of
vitronectin/PAI-1 complexes, whereas shaded bars represent binding of mixtures
treated with tPA. Error bars represent standard errors. Panel B, the effects of
dissociation of PAI-1 from vitronectin complexes were evaluated by size-exclusion
HPLC. Chromatograms corresponding to vitronectin alone (dotted line), equimolar
mixtures of vitronectin and PAI-1 incubated for 1 hour (dashed line), and mixtures of
vitronectin and PAI-1 incubated for 1 hour followed by treatment with tPA (solid
line), are shown.
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indicates that active PAI-1 is present in these high molecular weight complexes formed at
1 hour. From the decrease in peak height eluting at the void volume of the column, the
findings also indicate that some of the complexes can disaggregate when tPA neutralizes
PAI-1. However, at longer times, adding tPA to the mixtures has little effect, indicating
that the aged vitronectin aggregates exhibit enhanced matrix binding that is independent
of PAI-1. This is an interesting finding that suggests that at early time points, the
vitronectin/PAI-1 complex relies heavily on the presence of PAI-1 for stability and
functionality. However, as the complexes assemble further along the time scale, PAI-1
becomes less important, indicating that stable contacts between self-associating forms of
vitronectin have formed.

Enhancement of Binding of Vitronectin/PAI-1 Complexes to ECM is Dependent on
Ionic Strength—As shown in Figure 2-6, increasing ionic strength can reverse the
association of vitronectin complexes with the matrix upon PAI-1 binding. At a 1 M NaCl
concentration, the enhancement of vitronectin binding is decreased by ~70%. These
results indicate that the binding of vitronectin/PAI-1 complexes to components of the
ECM is presumably mediated through ionic interactions like those that are known to
occur between vitronectin and glycosaminoglycans.
To ensure that these results are not because of an effect of ionic strength on the
interaction between PAI-1 and vitronectin, the binding of PAI-1 and vitronectin was
monitored at varying ionic strengths using a fluorescence-based assay with PAI-1 labeled
with the environmentally-sensitive fluorophore NBD (N,N’-dimethyl-N-(acetyl)-N’-(7-
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Fig. 2-6. Effects of increase ionic strength on PAI-1-mediated binding of
vitronectin to ECM. Vitronectin and active PAI-1 were mixed in a 2:1 ratio and
incubated for 1 hour prior to addition to ECM-coated wells. The samples were added
to buffer of varying ionic strength for incubation with the matrices in wells. Results
are expressed as percentage of binding relative to samples in PBS taken as 100%.
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nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine). As PAI-1 has no cysteine residues in
its wild-type form, site-directed mutagenesis to engineer in cysteines at chosen sites
offers a valuable tool for labeling PAI-1 with reporter probes in strategic locations, like
those that can be used to signal a ligand-binding event. Here, a serine-to-cysteine
mutation at residue 119 that was engineered into the wild-type backbone of PAI-1 was
labeled with NBD, where the placement of NBD is within the vitronectin-binding site of
PAI-1. Using NBD-labeled PAI-1, an equilibrium titration experiment was carried out by
adding in increasing amounts of vitronectin to a constant concentration of PAI-1 and
monitoring the changes in fluorescence intensity as a function of vitronectin
concentration. Binding of native, monomeric vitronectin to the NBD-labeled PAI-1
resulted in a 50% enhancement in fluorescence intensity compared to labeled protein
alone. This enhancement is indicative of vitronectin binding, as this event results in a
shift of the NBD probe on PAI-1 into more hydrophobic surroundings, i.e. the
vitronectin/PAI-1 binding interface.
Binding isotherms for NBD-S119C-PAI-1 and vitronectin, in the presence of both 150
and 500 mM NaCl, are shown in Figure 2-7, titration of NBD-labeled PAI-1 with
vitronectin resulted in a binding isotherm that has a sigmoid shape. Allosteric binding
isotherms were observed, reflecting a complex association phenomenon consistent with
analytical ultracentrifugation studies that demonstrate a non-stoichiometric binding of
PAI-1 and vitronectin accompanied by self-association of vitronectin [127]. Under both
ionic strengths, a K0.5 of ~60 nM and a Hill coefficient of 2.2 were obtained. Differences
observed in the maximal fluorescence change observed with the two salt concentrations
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Fig. 2-7. Fluorescence experiments using NBD-labled PAI-1 demonstrate that
PAI-1-binding to vitronectin is not influenced by ionic strength. Small volume
aliquots of monomeric vitronectin were added to a 2-ml sample of NBD-labeled
S119C-PAI-1 at a final concentration of 0.2 µM. Binding was measured by
monitoring the increase in the fluorescence emission of NBD (emission at 525 nm)
upon vitronectin binding to PAI-1. Experiments were performed at NaCl
concentrations of 0.15 M (open circles) and 0.50 M (solid circles). Smooth curves
show fits to the Hill equation.
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are presumably because of intrinsic properties (e.g. quantum yield, exposure to solvent,
quenching ) of the fluorophore at the tow ionic strengths. Salt-dependent quenches of
fluorescence are a well-established phenomenon in photobiophysics [128]. These
findings demonstrate that similar complexes form between PAI-1 and vitronectin
regardless of the ionic strength of the solution environment. Furthermore, they argue that
the ionic-strength dependent effects observed in Figure 2-6 reflect dissociation of the
complexes from the ECM rather than dissociation of PAI-1 from vitronectin.

Multimerization Promoted by PAI-1 Binding Enhances the Interaction of Vitronectin
with Cell Surface Receptors—If vitronectin/PAI-1 complexes have a propensity to
become matrix-associated, a plausible corollary is that adhesive properties of the
complexes will be affected. To test the effects on adhesive properties of vitronectin that
may be affected upon PAI-1 binding, we applied a cell-binding assay using rabbit smooth
muscle cells (SMCs) and radiolabeled vitronectin. Incubation of vitronectin with PAI-1
resulted in an increase in the amount of vitronectin that adhered to SMCs (Figure 2-8).
Although active PAI-1 caused a nearly 2-fold increase in vitronectin binding to SMCs,
latent PAI-1 did not have any effect. These findings coupled with the HPLC results
described above indicate that PAI-1 binding to vitronectin results in the formation of
large complexes that are more adhesive to cell surfaces than the monomeric (circulating)
form of vitronectin.
To further investigate the effects of PAI-1 binding on adhesive properties of vitronectin
to cells, a solid-phase binding assay using purified integrins was employed. Similar to
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Fig. 2-8. PAI-1 enhances the binding of radiolabeled vitronectin to smooth
muscle cells. Rabbit smooth muscle cells were incubated 32P-vitronectin with or
without PAI-1. Control cell binding experiments also were conducted using latent
PAI-1. Protein-cell mixtures were incubated at 37 °C for 1 hour followed by
centrifugation at 12,000 x g to pellet cells. Cell pellets were washed with PBS and
measured for radioactivity in a Beckman LS3801 scintillation counter.
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the binding to SMCs, vitronectin showed an increased binding to GPIIbIIIa- or αVβ3coated ELISA plates when incubated with active PAI-1 (Figure 2-9, panels A and B).
Over a wide range of concentrations, a consistent enhancement of vitronectin binding
was observed; this finding was apparent at concentrations as low as 10 nM vitronectin
and PAI-1. The binding was saturable with respect to vitronectin (panel A) or PAI-1
(panel B). This effect was not observed with latent PAI-1 (panel A). Ratios of PAI-1 to
vitronectin that exceed 1:1 give maximal binding to integrins, presumable reflecting the
nonstoichiometric association of the two proteins [127]. These observations give further
evidence that PAI-1-induced multimerization of vitronectin is correlated with
enhancement in binding to cell surfaces.
A cursory evaluation of the mechanism by which PAI-1 enhances the association with
integrins as described above involved experiments that measured several properties
inherent to integrins and PAI-1 as partners with vitronectin in the binding phenomena.
Integrin binding to ligands occurs through a variety of mechanisms, some of which
involve metal-dependent interactions. Quite strikingly, the binding of vitronectin/PAI-1
complexes to GPIIbIIIa is abolished in the presence of EDTA (Figure 2-10). Binding of
uncomplexed vitronectin to the receptor was also diminished in the presence of EDTA.
Additionally, ionic strength dependence was observed for vitronectin binding to
GPIIbIIIa. Binding of the vitronectin/PAI-1 complexes was diminished significantly
when measured in the presence of 0.5 and 1.0 M NaCl, respectively. Furthermore,
binding of the complexes to the receptors was reduced when tPA was added and the
serpin-protease complexes dissociate from vitronectin. As shown in Figure 2-10, this
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Fig. 2-9. PAI-1-induced multimerization enhances the binding of vitronectin to
GPIIbIIIa. Panel A, vitronectin was pre-incubated with an equimolar amount of
active PAI-1 (●) or with integrin-binding buffer alone (○) for 1 hour at 37 ºC. A
control using a high concentration a high concentration of latent PAI-1 is shown (▲).
These solutions were then incubated with GPIIbIIIa-coated ELISA wells as described
in Materials and Methods. Following a 1-hour incubation at 37 ºC, wells were
washed and bound vitronectin was detected using an anti-vitronectin IgG. Results
are given in absorbance units at 405 nm. Panel B, varying concentrations of PAI-1
were mixed with a fixed concentration of vitronectin (20 nM) and pre-incubated for 1
hour at 37 ºC. Protein samples were then incubated for 1 hour with GPIIbIIIa-coated
(○) or αVβ3-coated (▲) ELISA wells as described in Materials and Methods. Bound
vitronectin was detected again by an anti-vitronectin IgG. Results are expressed as
an increase relative to the binding of vitronectin in the absence of PAI-1.
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Fig. 2-10. Effects of EDTA, ionic strength, and addition of tPA on PAI-1mediated binding of vitronectin to GPIIbIIIa. Vitronectin and active PAI-1 were
mixed in a 2:1 ratio and incubated for various times prior to addition to integrincoated wells. The binding of both monomeric and PAI-1-complexed vitronectin to
GPIIbIIIa were measured in the presence and absence of 10 mM EDTA. Also shown
are the effects of varied ionic strength and addition of tPA on the binding of
vitronectin/PAI-1 to GPIIbIIIa. Results are expressed as the relative binding
compared with that of untreated monomeric vitronectin with integrin-coated wells
(value normalized to 1). Error bars represent standard errors.
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effect is notable at 1 hour in experiments evaluating association with GPIIbIIIa. In fact,
the dependence of integrin binding on the presence of PAI-1 in the complexes at the 1hour time point is more pronounced than was observed in the matrix binding experiments
(Figure 2-5 panel A). However, these effects are minimized at longer times with both
integrins (data not shown) and matrices (Figure 2-5 panel A) when latent PAI-1
accumulates and oligomeric vitronectin prevails.

Discussion
Proper cell adhesion and migration is required for the maintenance of homeostasis;
alterations in these processes can lead to pathological situations such as impaired blood
clotting and wound healing. In addition, tumor cells can modify their own adhesive
properties and acquire the ability to exit residing tissues and travel to other sites and
metastasize. Investigation into both normal and pathological processes related to cell
adhesion and migration represents an important area of clinical research and a focus of
this work. The study presented here considers vitronectin and PAI-1, and the potential
roles they may play in cellular adhesion, specifically through the ability of PAI-1 to
induce the transition of vitronectin to a multivalent form.
Both PAI-1 and vitronectin have been widely studied as regulators of cellular adhesion.
As discussed in Chapter 1, vitronectin has also been shown to localize to focal adhesion
sites and promote cell spreading and migration through its ability to interact with cell
surface proteins like uPA receptor and integrins [41]. Most of the previous work with
PAI-1 has focused on a steric interference with integrin binding to vitronectin because of
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the juxtaposition of a primary PAI-1-binding site and the RGD motif near the N-terminal
end [135-137].
The studies discussed in this dissertation take a different perspective and aim to
investigate the role that PAI-1 plays in promoting self-association of vitronectin and what
effects it will have on the incorporation of complexes into the ECM displaying adhesive
properties. The hypothesis tested here suggests that PAI-1 represents a physiological
cofactor for the conversion of vitronectin into its matrix-associated (multimeric) form.
Several lines of evidence demonstrate that PAI-1 can induce vitronectin multimerization
through the formation of large higher-order complexes. Seiffert and Loskutoff were the
first to demonstrate that vitronectin formed large complexes upon binding to PAI-1, and
that these complexes were stable long after the disassociation of PAI-1 [119]. This study
also demonstrated that binding of PAI-1 and subsequent formation of vitronectin
multimers resulted in increased binding of vitronectin to conformationally-sensitive
antibodies and to heparin. Analytical ultracentrifugation approaches have offered an indepth study regarding complexes of PAI-1 and vitronectin (here in Chapter 4, and [127]),
with the demonstration that an early event in the pathway leading to vitronectin selfassociation is the formation of intermediate complexes consisting of a 4:2 ratio of PAI-1
to vitronectin. Over time, these complexes convert to stable vitronectin oligomers with
the conversion of PAI-1 to the inactive form.
It can be postulated that these intermediate vitronectin/PAI-1 complexes may serve to
couple functions of vitronectin in cellular adhesion with functions of PAI-1 in regulating
matrix degradation. Studies were designed to ask the following questions: Does
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multimerization of vitronectin, as a consequence of PAI-1 binding, result in enhanced
binding to integrins and components of the ECM? Does PAI-1 binding lead to a
“clustering” of binding sites for these ligands such that vitronectin becomes
“activated” into a multivalent, adhesive form? What types of interactions mediate the
interaction of PAI-1/vitronectin complexes with integrins and the ECM? How does the
temporal assembly of higher-order PAI-1/vitronectin complexes correlate with the
adhesive nature of vitronectin? A set of experiments were designed to follow the
multimerization event and correlate this with the association of vitronectin/PAI-1
complexes with cellular and matrix components in a solid-phase platform.
A time course was evaluated to monitor the formation of complexes between
vitronectin and PAI-1, extending to times sufficient to allow for the release of latent PAI1. This method demonstrated the immediate formation of large complexes containing
vitronectin and PAI-1, leading to observable vitronectin multimers after PAI-1 release.
The picture that emerged correlated well with results from both matrix- and cell-binding
studies, in that an enhancement in vitronectin binding to both ligands was associated with
complex formation between vitronectin and PAI-1. Comparing the HPLC time course
with a ligand-binding time course using ECM demonstrates a nice correlation between
augmentation of binding and formation of higher-order species. In addition, it is evident
that this enhancement of binding of vitronectin to the ECM is observable long after the
release of PAI-1, indicating that the effect is because of the conversion of vitronectin into
large multivalent species.
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A scheme shown in Figure 2-11 [128] helps in considering the dynamic processes that
occur in the vitronectin/PAI-1 interaction over a fairly long time scale up to 24-36 hours.
At all times after mixing of the two proteins, there are assembly and disassembly
processes that occur simultaneously. Immediately after mixing, PAI-1 binds to
vitronectin and promotes the formation of higher-order complexes. When tPA is added
to the mixture, it binds to and neutralizes PAI-1, thus releasing it from vitronectin, and
yields a mixture of species including vitronectin multimers and dissociated monomers.
At extremely long times (e.g. 24 hours), all PAI-1 has converted to a latent form and is no
longer bound to vitronectin multimers, and therefore the addition of tPA has essentially
no effect. At intermediate times, represented by the 3-hour time point in Figure 2-11,
there are competing processes in which latent PAI-1 accumulates and tPA has less of an
effect in binding active PAI-1 and removing it from vitronectin complexes. These
competing processes explain in part the curious observation at 3 hours that tPA has little
effect on the association of vitronectin multimers with the ECM.
The findings presented in this study demonstrate the effects of PAI-1-induced
multimerization on the adhesive properties of vitronectin by correlating binding to cells,
integrins, and matrix proteins. Variations in the adhesive properties of monomeric and
self-associated forms of vitronectin induced by PAI-1 are reminiscent of earlier studies
demonstrating the altered effects of chemically-induced multimerization of vitronectin on
binding to cell surfaces and ECM components [47,61,65,118,129]. An important
example of this involves binding to the polyvalent ligand, heparin, with the artificiallydenatured, also polyvalent form of vitronectin that is responsible for an apparent
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Fig. 2-11. A model for association of vitronectin into complexes with altered
adhesive properties. This schematic illustrates the assembly of vitronectin/PAI-1
complexes, their association into higher-order multimers, and dissociation of latent
PAI-1 over time, and the neutralization of PAI-1 by tPA. Vitronectin is depicted as
blue ovals; PAI-1 by yellow ovals; and tPA by red ovals. Immediately upon mixing,
vitronectin and PAI-1 form higher-order oligomers that build upon complexes with a
1:2 vitronectin:PAI-1 stoichiometry. Within 1 hour of mixing, a considerable
amount of multimers have formed. Addition of tPA dissociates PAI-1 from
vitronectin and yields both stable vitronectin oligomers and dissociated monomers.
At extremely long times (e.g. 24 hours), all PAI-1 has converted to a latent form and
is no longer bound to vitronectin multimers, and as such tPA has little effect on
remaining complexes. During this time course, multimeric adhesive complexes of
vitronectin form in increasing amounts until a maximal level is reached.
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enhancement in binding that is attributed to changes in the stoichometry of binding rather
that to changes in the affinity for heparin binding [118]. In a similar fashion, changes in
the binding of vitronectin to matrix ligands such as glycosaminoglycans presumably
result from a conversion of vitronectin into a multivalent state.
As discussed in Chapter 1, several studies have demonstrated that PAI-1 can also
inhibit vitronectin binding to cell-surface receptors [135-139]. Although these
observations would seem at odds with the demonstration in this study of enhanced cell or
matrix binding in PAI-1-induced multimers, a careful consideration reveals that the
experiments cannot be easily compared. Indeed, the former studies used vitronectin
already in a chemically-induced (or plastic-coated) multimeric form, and therefore do not
evaluate the effects of complex formation followed by multimerization of
vitronectin/PAI-1. These studies, although informative, do not accurately reflect the
physiological events that can occur between vitronectin and PAI-1 in vivo. In contrast,
the approach of the studies described here are more physiological in nature, and lead to
the conclusion that PAI-1 is a physiological cofactor that can regulate the tissue
distribution and adhesive functions of vitronectin.
Immunohistological studies give evidence that vitronectin and PAI-1 become colocalized at sites of tissue injury and disease [102,111,123-126]. This chapter presents
the first support that these findings reflect the deposition of vitronectin/PAI-1 complexes
into tissues that result in local remodeling of the ECM linked to injury, necrosis, and
cancer. It is clear that investigation into the role of ligand-induced multimerization of
vitronectin is physiologically significant and demands attention. In light of this, we
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decided to study the role of PAI-1-induced multimerization of vitronectin in a living
human fibroblast system, and the results of this study are summarized in the following
chapter.
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CHAPTER 3
PLASMINOGEN ACTIVATOR INHIBITOR-1 PROMOTES THE
RELOCALIZATION OF VITRONECTIN TO THE
EXTRACELLULAR MATRIX*

*This chapter is a revised version of a manuscript under the same title that has been
submitted for publication in Biochemica et Biophysia Acta in 2005 by Kenneth H. Minor,
Cynthia E. Wilkins-Port, Christine R. Schar, , Srilalitha Kuruganti, Paula J. McKeownLongo, and Cynthia B. Peterson [140].
My contributions to this paper include: (1) aiding in the development and design of
experimental goals and procedures, (2) performing most experiments and collections of
data, (3) analyzing collected data, (4) designing how the results were illustrated, and (5)
writing the manuscript in collaboration with my mentor Dr. Cynthia Peterson.

Introduction
The findings described in Chapter 2 support a model in which binding to PAI-1 leads
to the structural conversion of vitronectin into a matrix-associating, activated form that in
turn displays altered adhesive properties [128]. This conversion involves the
multimerization of vitronectin to an adhesive form that is similar to one that develops
upon chemical denaturation, a form that also displays differences in cell/matrix adhesion
when compared to the circulating, monomeric form [47,65,129,130,141]. As discussed
in Chapter 1, vitronectin contains binding sites for cell-surface receptors including
integrins [31,46,60,65,130,136,137,141], syndecan and uPAR [60,142]; it also harbors
sites specific for components of the ECM, including collagen [36,37,52,143] and GAGs
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[47,117,144,145]. This property of vitronectin endows the protein with the unique ability
to couple functions related to both cell adhesion and matrix binding.
The premise underlying this study is that multimeric vitronectin found within tissues
is produced by physiological stimuli, in particular through the interaction of circulating
vitronectin with biological ligands such as PAI-1. Several studies have identified
structural modifications in vitronectin that result from the interaction with PAI-1
[119,128]. In Chapter 2, a series of experiments are presented that show evidence that
PAI-1 binding to vitronectin leads to the formation of higher-order complexes that exhibit
altered binding to cellular integrins and the ECM in isolated systems using purified
components [127,128]. It is proposed that elevated PAI-1 levels, which are correlated
with physiological stress following injury or during cancer progression, promote
conversion of plasma vitronectin to an altered, multimeric form that becomes deposited
onto the ECM. At that locus, the protein assumes its role in promoting cell adhesion
and/or matrix remodeling.
In the following studies, this hypothesis is tested for the first time in cell culture.
Does PAI-1-induced multimerization associated with increased deposition of
vitronectin in the ECM? Does this event result in an increase in binding of vitronectin
to cell-surface receptors? What cell-surface receptors and matrix components are
involved? Does PAI-1 co-localize with vitronectin at the cell-matrix interface? The
importance of PAI-1 binding to vitronectin leading to structural and functional changes
manifested by cellular uptake and deposition in the ECM are addressed using cultured
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fibroblasts treated with the circulating form of vitronectin or with PAI-1/vitronectin
complexes.

Materials and Methods
Proteins and Antibodies—Vitronectin was isolated from human plasma using a
purification strategy described previously [146,147], which is a modified procedure
designed by Dahlback and Podack [134]. Recombinant wild-type PAI-1, stable mutant
PAI-1 (14-1B), tPA, and monoclonal anti-PAI-1 antibody were obtained from Molecular
Innovations, Inc. Monoclonal antibody against αvβ5 was purchased from Chemicon.
Fluorescently labeled secondary antibodies (anti-rabbit and anti-mouse IgG) used in
immunostaining came from Molecular Probes, Inc., as well as biotinylation kit used for
labeling vitronectin. RGDS peptide was purchased from Sigma. All cell culture
materials were obtained from ATCC.

Cell Culture—Human foreskin fibroblasts (A1-F) were a gift from Dr. Lynn AllenHoffman (University of Wisconsin, Madison, WI). Cells were maintained in Dulbecco’s
Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
For experiments, confluent cells grown in T75 flasks were removed by treatment with
trypsin, and re-seeded onto 24-well cell-culture plates or multi-chamber glass microscope
slides.
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Iodination of Vitronectin—Vitronectin was iodinated by incubating native protein
(200 µg) with 0.5 mCi Na125I in the presence of lactoperoxidase (10 µg/ml), glucose
oxidase (1 U/ml), and glucose (40 mM). The reaction was carried out for 5 minutes and
then stopped by adding bromophenol blue and 10 mg/ml tyrosine. Free iodine was
removed by size-exclusion chromatography using a G-25 Sephadex filtration column.
Radiolabeled vitronectin was stabilized with 0.1% phenylmethyl sulfonyl fluoride-treated
bovine serum albumin (BSA) and dialyzed against phosphate buffered saline (PBS).
Aliquots of vitronectin were stored at -70°C until use. Integrity of native vitronectin was
checked by SDS-PAGE and autoradiography. Specific activity was approximately 1
µCi/µg protein.

Binding and Degradation of Vitronectin—Experiments were carried out as
previously described [129,148]. For binding studies, ascorbate-treated A1-F fibroblasts
were grown as confluent monolayers in 24-well plates and incubated with 125I-labeled
vitronectin in either the native conformation or in the multimeric form as induced by
active human PAI-1. Multimeric vitronectin complexes were generated by incubating
vitronectin and PAI-1 at varying stoichiometric ratios in DMEM at 37°C for 30 minutes.
Added vitronectin (final concentration 2.5 µg/ml) was incubated with fibroblasts for 5
hours at 4°C to prevent internalization and degradation so to measure binding to the
monolayer solely. Following incubation, radioactive medium was removed and cell
layers were washed several times with ice-cold PBS to remove non-bound vitronectin.
Cell layers were solubilized in 1 N NaOH and radioactivity was measured by gamma
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counting. Bound vitronectin was determined to be the percent of 125I-vitronectin that
remained associated with the cell layer. As indicated, binding experiments were also
carried out to evaluate the effects of tPA-mediated release of PAI-1 from oligomeric
complexes.
Degradation experiments were carried out as above except that cultures were
incubated at 37°C. Vitronectin degradation was determined by measuring the level of
trichloroacetic acid (TCA) (10% final concentration) soluble radioactivity present in the
medium following a 5 hr incubation with 125I-labeled vitronectin. Background
degradation was determined in parallel wells with DMEM and 10% FBS in the absence
of cells. Percent degradation was calculated by subtracting background radioactivity, and
dividing by the total amount of 125I-vitronectin added to each well. For each degradation
sample, the amount of vitronectin bound to the cell layer was also determined by washing
cells and measuring radioactivity in solubilized monolayers.

Immunofluorescence Microscopy—Vitronectin was labeled (kit from Molecular
Probes, Inc.) on primary amines with biotin so that exogenously added protein could be
differentiated from that from cultured serum. Fibroblasts were cultured on glass
microscope slides with attached multi-well chambers. DMEM medium was added to
cells, including medium containing biotinylated vitronectin in both native and PAI-1induced multimeric forms. The final concentration of vitronectin was 25 µg/ml and in
formation of multimeric complexes, PAI-1 was pre-incubated with vitronectin for 30
minutes at a 1:1 molar ratio. Vitronectin-containing medium was added to cells and
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incubated at 37°C for 30 minutes to allow time for internalization. To prevent lysosomal
degradation, cultures were treated with medium containing chloroquine. At the end of
incubation, cells were washed three times with PBS and then fixed using 3.7%
paraformaldehyde (30 minute treatment at 37°C). Fixed cells were permeablized for 10
minutes at 4°C with cold buffer containing 0.5% Triton X-100, and then blocked with
PBS containing 3.5% BSA for 1 hr at room temperature. Anti-PAI-1 IgG (1:1000) and
fluorescein isothiocyanate (FITC)-conjugated streptavidin (to detect biotinylated
vitronectin) were added in PBS containing 1% BSA. Primary detections were carried out
for 1 hour at room temperature, followed by several washes using PBS. PAI-1 was
detected with AlexaFluor 568-tagged goat anti-mouse IgG by incubating for 1 hour at
room temperature. Following final washes in PBS, cover slips were added using antifade mounting media. Staining was observed with an Olympus epifluorescence
microscope and images were captured and transferred to Adobe Photoshop with a
Hamamatsu color 3CCD camera. Confocal imaging was performed using a Leica TC
SP2 laser-scanning confocal microscope.

Isolation of ECM from Fibroblast Monolayers—Cells were grown to confluence on
glass microscope slides and carefully removed from ECM using 0.02 M ammonium
hydroxide treatment for 10 minutes. Isolated matrices were washed 3 times using PBS
and slides were blocked with 3.5% BSA. Following blocking, biotinylated vitronectin
and PAI-1/vitronectin complexes were added to matrices in PBS and incubated for 1 hour
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at 37°C. Immunostaining of vitronectin and immunofluorescence microscopy was
carried out as described above.

Results
PAI-1 Binding Promotes Increased Processing of Vitronectin by Human A1-F
Fibroblasts—Results presented in Chapter 2 provide evidence that PAI-1 binding to
vitronectin induces formation of multivalent complexes that display altered binding to
purified cell-surface receptors and ECM components [128]. To determine if these effects
are observed in living cellular models, experiments were conducted to evaluate the
effects of PAI-1/vitronectin complex formation using human foreskin fibroblasts (A1-F)
grown as cell-matrix monolayers. Experimental procedures were adapted from published
work evaluating the effects of chemical alteration of vitronectin on the cellular binding
and processing of the protein by fibroblasts [129]. To follow binding and degradation of
vitronectin, the protein was labeled with Iodine-125 using a method that employs
lactoperoxidase and glucose oxidase [129]. Since the studies described here aim to
evaluate the effects of ligand-induced multimerization of the plasma form of vitronectin,
it was imperative that radiolabeling did not result in oligomerization.
As shown in Figure 3-1, labeling of vitronectin with iodine did not cause the
formation of disulfide-linked oligomers that are seen when the protein is altered by
treatment with urea. SDS-PAGE analysis under non-reducing conditions show the
formation of high-molecular weight complexes for the chemically-induced multimer of
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Fig. 3-1. SDS-PAGE analysis of iodinated-vitronectin. 125-Iodine-labeled native
vitronectin and chemically denatured vitronectin were analyzed by SDS-PAGE under
reducing and non reducing conditions. Gels were electrophoresed and dried followed
by exposure onto film.
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vitronectin also labeled with radioisotope. A very small amount of high-molecular
species (~200 kDa) was generated upon 125I-labeling of plasma vitronectin, with the
majority of protein present in the monomeric form. These results indicated that our
labeled protein would be appropriate for studies investigating the interaction of
vitronectin with fibroblast upon PAI-1-induced multimerization.
Figure 3-2 demonstrates that complex formation with PAI-1 results in an enhanced
level of vitronectin turnover by fibroblasts when cultures are incubated at 37°C for 5
hours. The PAI-1 effects on uptake and degradation of vitronectin by the fibroblasts are
dose-dependent, saturating at a PAI-1:vitronectin molar ratio near 2:1. These new
findings establish that higher-order species of vitronectin, which can arise in a biological
setting when bound to PAI-1, are degraded more effectively by cells than the monomeric,
circulatory form of vitronectin. This turnover is presumed to be a direct consequence of
increased binding of the complexes to the cell layer. Several experimental strategies were
pursued to test the mechanism of processing of the higher-order complexes by the
fibroblasts.

PAI-1 Promotes Increased Binding of Vitronectin to Human Fibroblast
Monolayers—The mechanism for increased cellular turnover of vitronectin induced by
PAI-1 involves a series of events, with binding to the cell-matrix layer as the obligatory
first step. To determine if PAI-1/vitronectin complexes exhibit enhanced binding to cell
surfaces and/or deposition of the protein onto the ECM of cultured fibroblasts, binding
experiments were conducted at 4 °C. Results in Figure 3-3 show increased association of
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Fig. 3-2. Vitronectin degradation by human fibroblasts is dependent on PAI-1
binding. Human fibroblasts were grown to confluence and treated with ascorbate
for 3 days as described in Materials and Methods. Confluent monolayers were
cultured in DMEM media containing exogenous 125I-labeled vitronectin either in its
native conformation or complexed with varying molar ratios of PAI-1. Degradation
was carried out over 5 hours at 37°C in DMEM, and the amount of vitronectin
degraded was determined by measuring the radioactivity present in TCA-soluble
fractions of cultured media. Results, initially calculated as the percent of vitronectin
degraded as described in Materials and Methods, are expressed as relative values
normalized to the maximal value observed at a PAI-1:vitronectin ratio of 8:1 (11 %
degradation). Error bars represent standard errors.
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Fig. 3-3. PAI-1 binding enhances the association of vitronectin with fibroblast
monolayers. Human fibroblasts were grown to confluence and treated with
ascorbate for 3 days as described in Materials and Methods. Exogenous 125Ilabeled vitronectin alone, or labeled vitronectin combined with varying molar ratios
of PAI-1, were added to the fibroblast monolayers. Cell binding was conducted
over 5 hours at 4°C in DMEM, and the amount of vitronectin bound was
determined by measuring the radioactivity present on monolayers washed 3 times
with PBS. Results, initially calculated as the percent of vitronectin bound as
described in Materials and Methods, are expressed as relative binding normalized
to the maximal value observed at a PAI-1:vitronectin ratio of 4:1 (2 % bound).
Error bars represent standard errors.
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125

I-vitronectin with fibroblast monolayers as the amounts of the serpin PAI-1 increase.

Again, the effect is dose-dependent, with maximal binding at a stoichiometry of
approximately 2:1 PAI-1/vitronectin.
To investigate the potential role of GAGs present on fibroblast monolayers, binding
studies were carried out using sodium chlorate, a competitive inhibitor in the binding of
sulfate to ATP sulfurylase, an enzyme involved in formation of the biological sulfate
donor, 3’-phosphoadenosine 5’-phosphosulfate [149,150]. This leads to the synthesis of
proteoglycans containing GAG chains that are depleted of sulfate groups [151-153].
Results presented in Figure 3-4 illustrate that binding of the PAI-1/vitronectin complexes
to cell monolayers is dependent on sulfated GAGs. When PAI-1/vitronectin complexes
were added to fibroblasts that had been pretreated for 2 days with chlorate, there was a
50% decrease in the relative level of vitronectin bound to the fibroblast monolayers.

Binding of Vitronectin/PAI-1 Complexes to Fibroblast Monolayers is Dependent on
the Presence of Active PAI-1—To test the potential role of PAI-1 in the binding of
vitronectin/PAI-1 complexes, experiments like those described in Chapter 2 using tPAmediated release of PAI-1 were utilized. Here, complexes of vitronectin and PAI-1 were
allowed to form for 5 minutes or 1 hour, and then complexes were treated with tPA to
dissociate bound PAI-1 and prevent any further binding of PAI-1 to vitronectin (i.e. tPA
was presented in saturating amounts relative to PAI-1). Results shown in Figure 3-5
demonstrate that release of PAI-1 from oligomeric complexes results in a significant
decrease in the amount of vitronectin associated with fibroblastic monolayers. These
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Fig. 3-4. Effect of chlorate treatment on vitronectin binding to fibroblast
monolayers in the presence and absence of added PAI-1. Confluent ascorbatetreated fibroblast monolayers were incubated for 2 days with 50 mM sodium
chlorate in DMEM supplemented with 10% FBS. Both chlorate-treated and nontreated cells were cultured in media lacking FBS and containing 125I-vitronectin
alone or vitronectin mixed with PAI-1 (4:1 molar ratio of PAI-1:vitronectin). Cell
binding was carried out as described in Materials and Methods. Results are
presented as the percentage of total vitronectin associated with monolayers,
compared to the amount present when PAI-1/vitronectin mixtures were added to
non-chlorate treated cells. Error bars represent standard errors.
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Fig. 3-5. Effect of tPA-mediated release of active PAI-1 on vitronectin binding
to fibroblast monolayers. Confluent ascorbate-treated fibroblast monolayers were
cultured in media lacking FBS and containing 125I-vitronectin mixed with PAI-1
(2:1 molar ratio of PAI-1:vitronectin). Following mixing, tPA was added in
equimolar amounts with PAI-1 at time of mixing or 1 hour after. Cell binding was
carried out as described in Materials and Methods. Results are presented as the
percentage of total vitronectin associated with monolayers, compared to the amount
present when PAI-1/vitronectin mixtures were added in the absence of tPA. Error
bars represent standard errors.
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results were identical regardless of when tPA was added following mixing of PAI-1 and
vitronectin, indicating the requirement for PAI-1 in complex formation and stability.
Findings presented in Chapter 4 of this dissertation demonstrate the involvement of PAI1 in directly stabilizing higher-order complexes formed with vitronectin. Importantly,
these results do not exclude the possibility that PAI-1 mediates the interaction of the
vitronectin/PAI-1 complex directly by self-engagement with cell/matrix components.
Indeed, previous evidence has shown that PAI-1 can interact with certain ECM
molecules, including glycosaminoglycans [154,155]

Immunofluorescent Localization of Vitronectin and PAI-1 Demonstrates the
Effects of Complex Formation on Fibroblast Association and Degradation—To
complement these data indicating that PAI-1 complexing of vitronectin promotes its
increased binding to fibroblasts, and subsequent endocytosis and degradation,
immunofluorescent microscopy was used to evaluate the cellular binding and
internalization of vitronectin and PAI-1. Fibroblasts were grown to confluence or nearconfluence and were incubated with medium containing biotinylated-vitronectin alone or
in complex with PAI-1. The mixtures were incubated at 37 °C for 30 minutes, a time
sufficient for binding and endocytosis by cells. Cells were fixed, permeablized and
stained for vitronectin using fluorescently-tagged streptavidin. Images presented in
Figure 3-6 demonstrate noteworthy differences, with no detectable binding of monomeric
vitronectin (panel A), compared to clear association of PAI-1/vitronectin complexes
(panel B) with the cell layers. The addition of PAI-1 to vitronectin results in a stronger

79

A

C

10 µm

10 µm

B

D

10 µm

10 µm

Fig. 3-6. Effects of PAI-1-induced formation of higher-order complexes on the
cellular localization of vitronectin on human fibroblasts. Human fibroblasts
were cultured on glass microscope slides in DMEM treated with chloroquine. Cells
were incubated with biotinylated vitronectin either in the native conformation
(panel A) or as multimers induced by PAI-1 (panels B-D). Cell monolayers were
incubated at 37°C for 30 minutes and then washed, fixed with paraformaldehyde,
and permeabilized with Triton X-100. Vitronectin was detected using FITCconjugated streptavidin. Fibroblasts shown in panels A and B were present as
confluent layers whereas those shown in panels C and D were non-confluent.
Panel D shows a phase-contrast image with overlaying staining for PAI-1 induced
multimers of vitronectin. Magnification was 40x (panels A-C) or 100x (panel D).
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staining intensity for vitronectin associated with the ECM and/or the A1-F fibroblasts.
Similar findings were observed for non-confluent cells, and also present is a punctate
staining pattern for vitronectin that clearly co-localizes to fibroblasts (panel C). This
punctate pattern is shown more clearly in the 100X magnified image presenting a phasecontrast image combined with immunostaining for vitronectin (panel D). This magnified
image shows the cytosolic localization of these foci, suggesting that vitronectin is taken
up into intracellular vesicles. All images in Figure 3-6 were recorded on cells treated
with chloroquine, experimental conditions that gave larger foci compared to cells
cultured in the absence of chloroquine. Chloroquine inhibits the degradation of proteins
by raising the pH within the lyososome from its optimum. The accumulation of larger
foci under these conditions indicates that the punctate staining pattern observed reflects
the processing of vitronectin within lysosomal vesicles. These results on the PAI1/vitronectin complexes have been followed up with confocal microscopy that confirms
these foci to be cytoplasmic vesicles rather than cell surface or matrix-associated
structures.
As mentioned above, the immunostaining pattern that demonstrates an increase in
vitronectin association with the cultured fibroblasts has features correlated both with
increased binding to and processing by the cells (through lysosomes). To directly test
whether there is an increase in vitronectin deposition in the ECM, immunolocalization
experiments were implemented with matrices produced by the fibroblasts in culture.
Cells were grown to near confluence and exposed to monomeric vitronectin or PAI1/vitronectin mixtures as described above. After the 30-minute incubation with the
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fibroblast cultures, the cells were removed from the underlying ECM by treatment with
ammonium hydroxide so that images of the isolated acellular matrix could be recorded.
As shown in Figure 3-7, there is a marked increase in the amount of vitronectin staining
associated with ECM fibrils when PAI-1 is present to promote formation of the higherorder vitronectin complexes. Figure 3-7 (panel B) shows the result at 40X magnification,
where there is clearly more immunostaining in the presence of PAI-1 compared to
experiments with monomeric vitronectin alone (panel A). Two different images recorded
at 100X magnification show staining patterns observed with the PAI-1/vitronectin,
representing the somewhat amorphous staining patterns observed in some fields (panel
C) and also the clear fibrillar patterns observed in other regions of the ECM (panel D).

To test the postulate that vitronectin and PAI-1 in the higher-order complexes are
internalized together for processing within the same intracellular vesicles, dual staining
experiments were carried out using both biotinylated vitronectin and monoclonal
antibodies directed against PAI-1. Images in Figure 3-8 (panels A and B) demonstrate a
similar staining pattern for vitronectin and PAI-1 when the proteins were added to
fibroblast cultured on microscope slides and treated with chloroquine. A merged image
(panel C), shows a co-localization pattern for vitronectin and PAI-1 when the individual
stains are overlaid. Confocal analysis also demonstrated the intracellular co-localization
of most of the positively stained vesicles (data not shown). These findings support a
mechanism by which PAI-1 associates with vitronectin into higher-order complexes that
exhibit enhanced association and degradation by fibroblasts. It appears from these
studies that the two proteins in the complex are internalized in the same fashion.
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Fig. 3-7.
Immunofluorescent localization of vitronectin demonstrates
enhanced binding of higher-order PAI-1/vitronectin multimers to ECM. A1F fibroblasts were grown to confluence on glass slides and then removed using
0.02 M ammonium hydroxide. Isolated ECM was washed with PBS and then
incubated with biotinylated vitronectin in the native form or in the PAI-1 induced
multimeric form in DMEM for 1 hour. Vitronectin bound to the matrix was
detected using FITC-conjugated streptavidin. Panel A represents ECM isolated
from cells cultured with native vitronectin and Panels B-D represent ECM
isolated from those cultured with vitronectin in complex with PAI-1.
Magnification was 40X (panels A and B) or 100x (panels C and D).
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Fig. 3-8. Fluorescent microscopy demonstrates the co-localization of vitronectin
and PAI-1 on human fibroblasts. Human fibroblasts were cultured on glass
microscope slides in DMEM treated with chloroquine as described in Materials and
Methods. Cells were subsequently incubated with DMEM containing biotinylated
vitronectin in complex with PAI-1. Cell monolayers were incubated with the
complexes at 37 °C for 30 minutes and then washed, fixed with paraformaldehyde,
and permeabilized with Triton X-100. Vitronectin was detected using streptavidin
(panel A) and PAI-1 was detected using a monoclonal antibody raised against human
PAI-1 (panel B). The image in panel C represents an overlay of vitronectin and PAI-1
immuno-staining. All images were collected at 40x magnification.
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Turnover of PAI-1/Vitronectin Complexes by A1-F Fibroblasts is Partially
Integrin-Dependent—To investigate the mechanism of uptake of the PAI-1/vitronectin
complexes by the cells, the potential role of integrins was tested. It was previously
shown that the chemically altered multimeric vitronectin is internalized by human
fibroblasts in an integrin-dependent fashion, specifically via αvβ5 [65,129,141]. In this
study, an antibody specific for the αvβ5 integrin and an RGDS peptide were used to carry
out competition studies for cell turnover of vitronectin. As shown in Figure 3-9 (panel
A), the antibody and the RGDS peptide only partially inhibited the degradation of the

higher-order vitronectin complexes with PAI-1 (approximately 15% and 30%,
respectively). These results indicate that other, possibly non-integrin mediated, processes
are involved in the uptake and degradation of vitronectin. At least one possiblity would
be a direct involvement of PAI-1 in uptake of vitronectin complexes, potentially through
interactions with PAI-1-receptors like uPAR and low-density LRP receptor.
Results in Figure 3-9 (panel A) also demonstrate that degradation of PAI-1 induced
multimers of vitronectin is inhibited by chloroquine. Chloroquine diminished the
degradation of 125I-labeled vitronectin complexes with PAI-1 by greater than 50%. These
findings are in agreement with the augmented punctate staining pattern observed by
microscopy (above) and also with studies on chemically-induced multimeric forms of
vitronectin indicating that the uptake of the protein by integrins is coupled to lysosomal
degradation [65,129,141].
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Fig. 3-9. Cell turnover and binding experiments demonstrate the role of
integrins and native PAI-1 in the turnover of vitronectin by fibroblasts. Panel
A: Degradation experiments using exogenous 125I-labeled vitronectin in complex
with PAI-1 demonstrate the partial inhibition of vitronectin turnover by chloroquine,
antibody specific for avb5 (50 µg/ml), and RGDS peptide (0.5 mM). Panel B:
Binding experiments were implemented using vitronectin alone, vitronectin plus
wild-type PAI-1, or vitronectin plus the 14-1B stable mutant form of PAI-1. Results
in both panels are presented as the percent of degradation or binding of vitronectin
relative to the levels observed for vitronectin + PAI-1 (1:4 vitronectin:PAI-1 molar
ratio) in the absence of inhibitors. Error bars represent standard errors.

86

Enhancement of Vitronectin Binding to Fibroblast Monolayers is Dependent on
the Native Structure of PAI-1—A unique property of PAI-1 among other serpins is its
propensity to convert to a latent, inactive form that can neither inhibit plasminogen
activators, nor bind to vitronectin. Stable forms of PAI-1 that do not readily convert to
the latent form have been generated from site-directed mutagenesis studies incorporating
amino acid replacements in the central β-sheet core of the protein [156-160]. Because of
potential experimental complications that may arise due to the inherent slow rate of
conversion to latency by native PAI-1, many researchers have opted in their studies to
use the stable variant of PAI-1 that has been best characterized [157,158] This PAI-1
variant, denoted 14-1B, contains 4 mutations (Asn150His; Lys154Thr; Gln319Leu;
Met354Ile) and is the form of PAI-1 that has been crystallized [160]. These mutations
result in a delay in the transition of PAI-1 to latency by approximately 70-fold, with no
reported change in inhibition of tPA or uPA. Although many current structural and
functional studies rely on the use of the stable 14-1B PAI-1, it appears that there are some
distinctions between native PAI-1 and the stable conformer. For example, uPA reacts
differently with native PAI-1 and the 14-1B variant in the presence of the non-ionic
detergent Triton X-100, with a reduction in the inhibitory activity against both forms
[161]. Because of the possibility that there may be important structural and/or functional
differences, the stable 14-1B variant was compared to native PAI-1 in the fibroblast
binding assay.
As shown in Figure 3-9 (panel B), the enhanced binding by fibroblasts of the PAI1/vitronectin complexes is observed with native PAI-1, but not with the 14-1B variant.

87

When 125I-labeled vitronectin was complexed with the 14-1B stable variant of PAI-1, no
differences were seen in vitronectin binding to the cellular monolayers when compared to
monomeric vitronectin. Therefore, the function of PAI-1 in promoting higher-order
complexes that assume an adhesive role in binding to cells and matrices clearly relies on
the native structure of PAI-1. Interestingly, results in Chapter 4 evaluating the ability of
PAI-1 to promote higher-order oligomerization of vitronectin demonstrate that 14-1B
PAI-1 does not induce oligomerization to the extent that the wild-type form does.

Discussion
The study presented in this chapter strongly supports the findings discussed in
Chapter 2, where vitronectin/PAI-1 complexes displayed enhanced association with both

cell surface receptors and isolated ECM when compared to monomeric vitronectin alone.
By utilizing a living system, we gain more physiological support regarding our model
that vitronectin/PAI-1 complexes display adhesive properties that develop through the
process of ligand-induced multimerization of vitronectin. Our system for studying our
model is based on using human fibroblast, and was optimized for studying the adhesive
properties of vitronectin by our collaboraters (Dr. Paula McKeown-Longo laboratory) at
Albany Medical School in New York. The results presented here provide new evidence
that PAI-1/vitronectin complexes display enhanced interactions with human fibroblast
monolayers, an event that would be significant during homeostatic responses such as
wound healing and tissue remodeling. In this study, uptake and degradation of
vitronectin was monitored to follow the engagement of the protein with fibroblast cell
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surfaces. It is important to note that the aim of this study was to merely use this system
to indirectly monitor the active engagement of vitronectin with fibroblast cell surfaces,
and not to specifically address questions regarding the physiological importance and
consequences of vitronectin and/or PAI-1 clearance and degradation. Although this latter
aim is important and several hypotheses might be drawn based on the results presented
here, our intention was focused mainly on evidence of cell surface binding. In fact, it
would be in the interest of this laboratory to evaluate other downstream consequences of
vitronectin binding to cell surface receptors including signaling, cytoskeletal
rearrangements, and cellular motility.
When found in higher-order complexes with PAI-1, vitronectin interacts with cell
monolayers and is subsequently endocytosed and degraded to a greater degree than native
vitronectin. Maximal effects are observed at a stoichiometry near 1:2 (vitronectin:PAI1), in keeping with the biophysical analyses in Chapter 2 of complexes formed in the
isolated systems that show the same binding stoichiometry [128]. Interestingly, PAI-1
seems to be required for enhanced binding of complexes to monolayers, as demonstrated
at early times by the addition of tPA. Immunofluorescent microscopy demonstrates the
enhanced uptake of vitronectin when bound to PAI-1, documents increased deposition of
the protein in the ECM, and shows that both proteins are present within similar
intracellular vesicles. Binding of PAI-1/vitronectin complexes is dependent on properly
sulfated GAGs on the fibroblast monolayer. Recent work with an HT1080 cell line has
demonstrated that binding of vitronectin to the cell layers is mediated via a specific
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interaction of the basic heparin-binding domain of vitronectin interacting with the
transmembrane heparan sulfate proteoglycan, syndecan [162]
Interestingly, the effects also are limited to complexes formed with the native form of
PAI-1. Specific differences between native PAI-1 and the 14-1B stable variant must
await further detailed structural analysis; it is not possible at this time to attribute
properties of the complexes either to structural nuances or to differences in the kinetics of
formation/breakdown of the complexes that are tied to the active to latent conversion of
PAI-1. However, analytical ultracentrifugation results presented in the following chapter
demonstrate clear differences in the effectiveness of wild type and the stable form of
PAI-1 in promoting formation of higher-order complexes. The hypothesis that PAI-1
confers an adhesive role on vitronectin via formation of higher-order species is supported
by these data and also by the differences observed in our cell-matrix binding experiments
for the two forms of PAI-1.
The mechanism by which PAI-1/vitronectin complexes that associate with the
cell/matrix layer in fibroblast culture are subsequently taken up and degraded depends to
an extent on the cell surface integrin, αvβ5. The evidence for involvement of this receptor
comes from inhibition studies presented here using antibodies specific for αvβ5, as well
as RGD peptides. McKeown-Longo et al. [141] have demonstrated a role of this integrin
in the removal of chemically-altered vitronectin from the ECM of fibroblast monolayers
and subsequent lysosomal degradation. We demonstrate only a partial inhibition,
indicating the potential role of other receptors and/or potential non-RGD-dependent
integrin binding sites on vitronectin [46] Another plausible mechanism that needs further
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consideration is the direct role of PAI-1 in associating higher-order vitronectin complexes
with cell surfaces that leads to uptake and degradation. The presence of PAI-1 in the
higher-order complexes should influence the internalization of vitronectin/PAI-1
complexes, via interactions with other known cell-surface receptors for PAI-1 such as
uPAR and/or the low-density lipoprotein receptor-related protein.
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CHAPTER 4
A MECHANISM FOR ASSEMBLY OF COMPLEXES OF
VITRONECTIN AND PAI-1 FROM SEDIMENTATION VELOCITY
ANALYSIS*

*This chapter is a revised version of a manuscript under the same title published in the
Journal of Biological Chemistry in 2005 by Kenneth H. Minor, Christine R. Schar, Grant
E. Blouse, Joseph D. Shore, Daniel A. Lawrence, and Cynthia B. Peterson [163].
Minor K. H., Schar C. R., Blouse G. E., Shore J. D., Lawrence D. A., and Peterson C. B.
A mechanism for assembly of complexes of vitronectin and plasminogen activator
inhibitor-1 from sedimentation velocity analysis. Journal of Biological Chemistry 280
(31): 28711-28720.
My contributions to this paper include: (1) aiding in the development and design of
experimental goals and procedures, (2) performing all experiments and collections of
data, (3) analyzing collected data, (4) helping initiate the development of the multisignal
analysis of sedimentation velocity data using the program SEDPHAT in collaboration
with Dr. Peter Shuck, (5) designing how the results were illustrated, and (6) writing and
publication of the work in collaboration with my mentor Dr. Cynthia Peterson.

Introduction
Results given in Chapters 2 and 3 [128,140] support a model in which binding to PAI-1
leads to the functional conversion, or “activation” [Bloemendal, 2004 #286;Minor, 2005
#347] of vitronectin from a circulating form into a tissue-associated, pro-adhesive form.
PAI-1-induced activation of vitronectin involves the formation of multivalent PAI1/vitronectin complexes that assemble into the ECM and readily associate with cell-
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surface receptors. What is the mechanism of assembly of higher-order PAI1/vitronectin complexes that are targeted to the ECM? What types of intermediates
and higher-order species are formed? What are the concentration- and timedependencies of the assembly process?
Sedimentation velocity experiments were used to observe the types of vitronectin/PAI1 that build off the 1:2 and 2:4 (vitronectin:PAI-1) complexes that are reported to form
[127]. These studies were also used to test the effects of time, ionic strength, and protein
concentration on the assembly of higher-order complexes. In short, the results described
in this chapter provide valuable information regarding the step-wise formation of
vitronectin/PAI-1 complexes, and give further insight into how complex formation
between these two proteins may support adhesive processes during wound healing and
tumor metastasis.
Vitronectin is localized predominantly in circulation with plasma concentrations in the
micromolar range. This concentration is constantly maintained with vitronectin present
in a monomeric form with a mass of approximately 62 kilodaltons. However, altered
multimeric forms of the protein are also found in certain tissues, especially those under
insult by vascular injury and/or tumor metastasis. Since most cells do not synthesize
vitronectin, the mechanism by which vitronectin becomes deposited into the ECM most
surely involves the active movement of the protein from circulation into the tissue matrix.
Although the ramifications of this circulation-matrix exchange of vitronectin are wellstudied, especially those related to the cellular adhesive properties, the actual mechanism
that results in this exchange is unknown.
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Mechanisms that recruit soluble matrix proteins to the pericellular environment are
well documented with several ECM components [2]. Denaturation and oligomerization
are mechanisms through which components like fibronectin, collagens, and
fibrinogen/fibrin become associated with tissue matrices. These two mechanisms can
result from enzymatic modifications as well as from interactions with biological ligands.
Regarding vitronectin, several studies have shown that certain ligands, including
plasminogen-activator type-1 (PAI-1), thrombin-antithrombin complex (T-AT), and
complement C5-6b, can form oligomeric structures with altered structural and functional
properties [119,121,164]. Is formation of oligomeric vitronectin-ligand complexes the
route through which vitronectin shifts from circulation to tissue? It is intriguing that each

of the vitronectin ligands mentioned here are all active in matrix remodeling processes,
including those linked to injury and metastasis of tissues.
A working hypothesis for this work poses that vitronectin becomes readily deposited
into tissues following damage from injury or cancer through a mechanism involving
ligand-induced formation of multivalent, adhesive complexes. Formation of these
complexes results in significant alterations in the functional properties of vitronectin that
in turn can have profound effects on both local and invading cells. Recent studies like
those presented in Chapters 2 and 3 demonstrate that the interaction of vitronectin with
the main inhibitor of fibrinolysis, PAI-1, results in the assembly of large complexes that
display enhanced association with cell-surface integrins and ECM components, including
glycosaminoglycans [128]. Relevant to these studies, localization experiments
demonstrate that PAI-1 levels increase following tissue injury and during tumor invasion,
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and that this is correlated with vitronectin/PAI-1 deposition into the surrounding matrix.
Intriguingly, PAI-1 expression is linked to several types of cancer, including cancer of
the lung, breast, colon, and skin [165-167], where it is speculated to play a role in tumor
angiogenesis and invasion. Importantly, high levels of PAI-1 correlate with later-stage
tumors and poorer clinical prognosis.
To begin obtaining information regarding the ability of PAI-1 to act as a regulator in
the compartmentalization of vitronectin between circulation and the ECM, we propose to
fully characterize the biochemical mechanism involved in the assembly of higher-order
vitronectin/PAI-1 complexes that become adhesive in nature. This characterization will
involve addressing the following questions:

Materials and Methods
Purification and Fluorescent Labeling of Vitronectin—Native, monomeric vitronectin
was purified from human blood plasma using a modified protocol of the method
developed by Dahlback and Podack [133,134]. For multi-wavelength studies,
vitronectin was labeled with FITC using a FluoReporter® protein labeling kit (Molecular
Probes, Inc., Eugene, OR) that labels primary amines. The molar ratio of dye to
vitronectin in the labeling reaction typically resulted in conjugation of ~2 fluorescein
molecules per vitronectin monomer; labeling ratios varied from 1.5 to 1.8 mol fluorescein
per mol vitronectin. The labeled vitronectin monomer was fully functional, with no
adverse effects of labeling on PAI-1 binding.
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Mutagenesis, Expression and Purification of Recombinant PAI-1—The stable I4-1B
mutant PAI-1 [158] and latent PAI-1 were obtained from Molecular Innovations, Inc.
The W175F variant [168] and PAI-1R (PAI-1 containing two amino acid replacements,
T333R and A335R [169]) were produced as described (and [169], respectively). The
recombinant human PAI-1 gene was cloned into the pET-24d vector (Novagen) as
described previously [170]. The M347C (P1'-Cys) form of PAI-1 was engineered by
site-directed mutagenesis using the Muta-Gene Phagemid In Vitro Mutagenesis kit (BioRad) using the mutagenic oligo 5’1125dGATCTCCTCGGGGGCACAGCGGGCTGAGACTAT-3’1093. All mutations were
confirmed by DNA sequencing of the full length PAI-1 gene.
Mutant and wild-type PAI-1 constructs were expressed in the E. coli strain
BL21(DE3)pLysS and purified as described [170]. Labeling of the P1'-Cys PAI-1 variant
with 5-iodoacetamidofluorescein (Molecular Probes) was carried out as described
previously with a labeling efficiency of 1-1.2 moles of 5-iodoacetamidofluorescein per
mole of PAI-1 variant. Latent PAI-1 that typically accumulated during the labeling
reaction was removed by affinity chromatography on immobilized β-anhydrotrypsin as
described [168]. All final unlabeled and P1'-fluorescein labeled preparations were shown
to be >98% active by detecting a stable, inactive acyl-enzyme complex with tPA using
SDS-PAGE analysis [168,170]. PAI-1 protein concentrations were determined from
absorption at 280 nm, using a Mr of 43,000 and extinction coefficients of 0.93 mL mg-1
cm-1 for wild-type PAI-1 or 0.83 mL mg-1 cm-1 for W175F PAI-1 [168]. Concentrations
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of labeled P1'-fluorescein PAI-1 were determined by the Bradford dye-binding assay
(Bio-Rad) using wild-type PAI-1 as the standard [171].

Sedimentation Velocity Experiments.—A Beckman Optima XL-I analytical
ultracentrifuge equipped with both absorbance and interference optical detection systems
were used to follow the formation of higher-order complexes between vitronectin and
PAI-1. Epon double-sector centerpieces were filled with 400 µl of samples containing
either vitronectin or PAI-1 alone, or mixtures of the two at varying molar ratios. All
samples were first dialyzed extensively against PBS. For all experiments, the dialysate
was loaded into the reference sector. Samples were centrifuged at a rotor speed of 50,000
rpm, and data were collected in fringes using interference optics and/or by absorbance at
494 nm, the extinction maximum for fluorescein.

Hydrodynamic Modeling of the Sedimentation Velocity Data—Sedimentation velocity
analyses were performed with the program SEDFIT (available online from
http://www.AnalyticalUltracentrifugation.com) as described in detail in [172] that carry out
size distribution analyses based on Lamm equation modeling [173-175]. Briefly, the
analysis of velocity profiles was performed by direct boundary modeling by distributions of
Lamm equation solutions c(s) with
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a(r,t) ≅

smax

∫ c(s)χ (s,F,r,t)ds + b(r) + β (t)
1

smin

(Eq. 1)

where a(r,t) denotes the measured absorbance or interference profiles at position r at time t,
b(r) and β(t) the characteristic systematic offsets [175], and χ1(s,F,r, t) solutions of the Lamm

equation
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(Eq. 2)
(with ω denoting the rotor angular velocity, D the diffusion coefficient and s the sedimentation
coefficient) at unit loading concentration. D and s are related via the frictional ratio F =
(f/f0) and the hydrodynamic scale relationship

D(s) =

2
kT s−1/ 2 (ηF)−3 / 2 ((1− ν ρ /ν )1/ 2
18π
(Eq.3)

(with η and ρ the solvent viscosity and density, respectively, and v the partial-specific
volume of the macromolecules, which were calculated using the software SEDNTERP
[174,176]. The non-linear regression with Eq. 1 was combined with the determination of
the best-fit weight-average frictional ratio, the best-fit meniscus position, and the algebraic
calculation of systematic time-invariant and radial-invariant noise components, and maximum
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entropy regularization at a confidence level of 0.70. Because these systematic signals are
arbitrary offsets introduced from the detection system, calculated systematic offsets can be
subtracted from the raw data without introduction of bias if the degrees of freedom in the
analysis are not reduced. Therefore, the final calculated best-fit offsets are subtracted from
the raw data for presentation purposes. In all calculations, both meniscus and frictional ratio
parameters were optimized by carrying out non-linear regression to obtain best fits. s-values
were converted to standard conditions in water at 20°C with the program SEDNTERP
[174,176].

Multi-Signal Analysis of Sedimentation Data for Fluorescently-Labeled PAI1/Vitronectin Mixtures—Sedimentation velocity data acquired simultaneously at different
signals (refractive index and absorbance) were globally modeled with a superposition of
component sedimentation coefficients ck(s) according to
K

aλ (r,t) ≅ ∑εkλ
k=1

smax

∫ c (s)χ (s,F
k

1

k,w

r,t)ds λ = 1K Λ, K ≤ Λ

smin

(Eq. 4)
where εkλ denotes the extinction coefficient (or generalized signal increment) of component k
at signal λ. This multi-signal generalization of Eq. 1 for heterogeneous protein interactions is
described in detail elsewhere [177], and was implemented in the software SEDPHAT
(http://www.AnalyticalUltracentrifugation.com). Briefly, the extinction coefficients were
pre-determined in separate experiments with each protein component alone. As a result, the
global modeling of data acquired at different wavelengths (or signals) permits a spectral
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distinction of the different sedimenting protein components, and allows for separate
deconvolution of the sedimentation coefficient distributions ck(s) of species containing
protein component k. Although this may lead also to slightly enhanced deconvolution of the
hydrodynamic separation, it has very similar properties as the c(s) with regard to the
influence of reaction kinetics on the obtained sedimentation coefficient distributions [173].
Reactions that are fast on the time-scale of sedimentation can be diagnosed by concentrationdependent peak positions in ck(s) which reflect the characteristic s-values of the reacting
system, but with different ck(s) still reflecting the correct stoichiometry [177]. Like c(s)
[173,174], reactions that are slow on the time-scale of sedimentation, as those studied in
the present communication, result in peak positions of ck(s) that correspond to different
sedimenting species.

Results
Characterization of PAI-1 and Vitronectin—The design of this study is to use
hydrodynamic methods to critically evaluate the formation of PAI-1/vitronectin
complexes. The SV method, which provides first-principle hydrodynamic information
concerning the size, shape and stoichiometries of macromolecules in heterogeneous
populations of interacting species, was adopted to characterize all complexes that form
upon PAI-1 binding to vitronectin.
As a first step in the analysis, experiments were conducted to characterize the
hydrodynamic properties of the individual proteins. Figure 4-1 shows the sedimentation
profiles for PAI-1 and vitronectin (Panels A and B, respectively), and the sedimentation
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Fig. 4-1. Sedimentation velocity analysis of PAI-1 and vitronectin using SEDFIT.
PAI-1 (3.5 µM) and vitronectin (3.5 µM) were analyzed individually by
ultracentrifugation at 50,000 rpm at 22 °C in a Beckman-Coulter XL-I analytical
ultracentrifuge. Sedimentation of proteins was monitored by interference detection.
SV data were analyzed using a continuous c(s) distribution model implemented in
the program SEDFIT. Partial specific volumes calculated on the basis of amino acid
and carbohydrate content for recombinant PAI-1 and human vitronectin were 0.74
and 0.705 ml·g-1 (listed in Table 4-I. The frictional ratio for each sample was a fitted
parameter in the SEDFIT analysis. Representative SV data, with global fits to each
data set, are shown for PAI-1 and vitronectin in panels A and B, respectively.
Resulting residuals for each analysis are given below each SV profile. Scans were
collected at approximate 11-min intervals. All data were included in the calculation
of c(s) distributions. c(s) distribution profiles for the two proteins are shown in panel
C (black line, PAI-1; blue line, vitronectin).
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coefficient distributions c(s) for both PAI-1 and vitronectin obtained from these analyses
(Panel C). For both samples, a major species is apparent, with peak s-values centered at
3.4 and 4.2 S for PAI-1 and vitronectin, respectively (Table 4-I). This observation was made
essentially independent of protein concentration. The small peak at a higher s-value of
6.2 S corresponds to a small amount of vitronectin dimer that appears to a variable extent
in purified vitronectin samples [178]. The quality of fit was high, with R.M.S. deviations
in both cases on the order of instrument noise. The observed s-values are consistent with
the monomeric state of the proteins, as summarized in Table 4-I that lists theoretical svalues for spherical proteins of this size for comparison. The best-fit frictional ratios
(f/f0) were 1.2 for PAI-1 and 1.5 for vitronectin (Table 4-I). This indicates a small degree
of shape asymmetry for PAI-1, which is compatible with the dimensions of the protein
known from crystallography [160]. For vitronectin, the series of SV experiments gave
consistently a frictional ratio of 1.5-1.7, indicating that the protein is significantly asymmetric.
This is supported by recent data using small-angle x-ray scattering on the native vitronectin
monomer that indicate that the shape of the molecule deviates significantly from that of a
sphere, yielding a bi-lobed shape with a maximal linear dimension of 110Å and average
hydrodynamic radius of ~30Å [179].

Mixtures of PAI-1 and Vitronectin Form Reversible Higher-Order Complexes—
With the goal of examining the mechanism of assembly of PAI-1/vitronectin complexes, SV
experiments were conducted on mixtures of the two proteins under varying conditions. As
described in Chapter 2 [128], the complexes formed can be observed in size-exclusion
chromatography and therefore dissociate slowly relative to the time-scale of the SV data
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Table 4-I: Sedimentation coefficients for PAI-1, vitronectin, and PAI-1/vitronectin complexes.
Partial
Maximum
Observed
Standard
Frictional
Molecular
Specific
Sedimentation Sedimentation Sedimentation
Ratio
Weight
Species
f
Volume
Coefficient
Coefficient
Coefficient
(f/f 0 )
a
-1 b
c
d
e
(Daltons)
(ml·g )
(ssphere )
(sobs )
(s20, w )
Vitronectin
(VN)
PAI-1

62,000

0.705

6.4 S

4.1 - 4.7 S

4.2 ± 0.2 S

1.5

43,000

0.740

4.3 S

3.2 - 3.7 S

3.4 ± 0.2 S

1.2

1 PAI-1: 1 VN

105,000

0.730

8.1 S

5.0 - 5.6 S

5.5 ± 0.2 S

1.5

2 PAI-1: 1 VN

148,000

0.730

10.2 S

6.0 - 6.7 S

6.5 ± 0.2 S

1.6

4 PAI-1: 2 VN

296,000

0.730

16.3 S

8.0 - 10.0 S

8.5 ± 0.5 S

1.8

a

The molecular weights of PAI-1 and vitronectin were calculated from both amino acid sequences and inclusion of
carbohydrate content.
b
Partial specific volumes for PAI-1 and vitronectin were calculated using SEDNTERP, whereas that for complexes was
fixed at 0.73.
c
Maximum sedimentation coefficients for a spherical, non-hydrated molecule calculated using SEDFIT.
d
Range in sedimentation coefficients observed under experimental conditions.
e
Sedimentation coefficients converted to standard conditions of 20 °C in water ± standard deviations; conversions
were made using the SEDNTERP and SEDPHAT programs.
f
Frictional ratios were determined using SEDFIT.
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acquisition. In other words, the dissociation constants of the complexes reflect rapid
association and slow dissociation rates. As a consequence, the peaks observed in c(s) analysis
reflect the sedimentation rates of the different species formed stably during the time-frame of
individual SV experiments [173,174,180]. Representative SV data on the PAI-1/vitronectin
mixture are shown in Figure 4-2. From the SV data acquired on an equimolar 8 µM mixture
of vitronectin and PAI-1, three major peaks at s-values of 6.5, 8.6, and 10.9 S, respectively,
were resolved in addition to several higher-order complexes ranging from ~12-25 S (Figure
4-3, panel A). Consistent with previous studies [119,127,128], the hydrodynamic profiles
show that PAI-1 binds to vitronectin and results in the formation of a variety of complexes,
including multiple higher-order oligomers.

To test the reversibility in assembly of these higher-order complexes, the equimolar 8 µM
PAI1/vitronectin mixture was diluted to varying concentrations that were analyzed by SV
(Figure 4-3, panels B and C). The results demonstrate that dilution over a concentration
range from 8 µM to 1.6 µM significantly alters the c(s) distribution profiles of the PAI1/vitronectin mixtures. As summarized in Table 4-I, the 1-5 S, 5.1- 7.4 S and 7.5-25 S
intervals of sedimentation coefficients are hydrodynamically consistent with free
vitronectin and/or PAI-1, intermediate 1:1 and 2:1 PAI-1/vitronectin complexes, and higherorder complexes, respectively. To quantify changes observed in Figure 4-3 (panels A-C)
peaks within these three different ranges of s-values were integrated to obtain total
amounts of the corresponding species (Table 4-II).

Only the distribution of PAI-1/vitronectin complexes, characterized by sedimentation
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0.5

Residuals
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Fig. 4-2. Sedimentation velocity analysis of an equilmolar PAI-1/vitronectin
mixture using SEDFIT. Equilmolar amounts of PAI-1 and vitronectin were mixed
for 1 h and were analyzed by SV at 50,000 rpm at 25 °C. This figure shows a
representative data set collected using interference optics for an 8 µM PAI1/vitronectin mixture. Data was analyzed using SEDFIT and the fitted data is given
by the solid lines, with residuals for the fit shown below the data. Scans are shown in
different colors for clarity. This type of analysis was carried out on varying
equilmolar mixtures of PAI-1 and vitronectin, results for which are given in Fig. 4-3
and Table 4-II.
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Fig. 4-3. c(s) distribution analysis of equimolar mixtures of PAI-1 and
vitronectin. Equilmolar amounts of PAI-1 and vitronectin were mixed for 1 h and
were analyzed by SV at 50,000 rpm at 25 °C using SEDFIT. Resulting c(s)
distributions for a dilutions series originating from an 8 µM PAI-1/vitronectin
mixture are shown in panels A (8µM mixture), B (3.2 µM mixture), and C (1.6 µM
mixture). A range of s values from 5 to 25 S is plotted for each mixture and two
ranges are identified in the top panel by the red (5.1-7.4 S; intermediate complexes)
and blue (7.5-25 S; higher order complexes) bars. Species with s values less that 5 S
are not shown here but are quantified in Table 4-II.
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Table 4-II: Assembly of PAI-1 and vitronectin into intermediate and higher-order
a
complexes.

Samples

Vitronectin +
wt PAI-1
Vitronectin +
wt PAI-1
Vitronectin +
wt PAI-1

Protein
Concentrations

Unbound
Intermediate Higher-Order
Proteins
Complexes
Complexes
(Fraction in s- (Fraction in s- (Fraction in srange from 1- range from 5.1- range from 7.5b
b
b
5 S ), %
7.4 S ), %
25 S ), %

8 µM Vitronectin
c
8 µM PAI-1
3.2 µM Vitronectin
c
3.2 µM PAI-1
1.6 µM Vitronectin
1.6 µM PAI-1c

a

26

24

50

25

45

30

30

64

6

Ranges in s -values were defined for integration according to criteria outlined in
Table 4-I, with species sedimenting with s -values in the range from 1-5 S
representing free proteins, species with s -values in the range from 5.1-7.4 S
representing intermediate 1:1 and 2:1 (PAI-1:vitronectin) complexes, and species
sedimenting with s-values greater than 7.5 S representing higher-order complexes.
b
Sedimentation data were evaluated as c(s) profiles, and data were integrated using
SEDFIT to determine the relative amounts of various PAI-1/vitronectin complexes
formed. Values were normalized by dividing the integrated values by the total
loading signal in fringes, and multiplying by 100 to obtain a percentage of the
various species formed. Errors are ± 5%.
c
C(s ) distributions of complexes with s-values >5 S for the three concentrations of
vitronectin and wild-type PAI-1 samples are shown in Figure 4-3, panels B-D.
Free proteins that sediment in the 1-5 S range are not shown in the figure, but the
integrations over this s -range are shown here.
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coefficients above 5 S, is shown in Figure 4-3. For each of the protein concentrations
tested, the proportion of signal corresponding to s-values between 1-5 S, representing free
PAI-1 and/or vitronectin, consistently was ~30 % of the total signal (not shown), consistent
with our prior sedimentation equilibrium studies on 1:1 mixtures of the two proteins [127].
The 5.1 - 7.4 S and 7.5 - 25 S integration ranges, corresponding to intermediate and
higher-order complexes, respectively, are indicated by colored bars above Figure 4-3
panel A. What is most significant about the findings is the apparent reversibility of

formation of higher-order complexes with s-values between 7.5-25 S, with a concomitant
emergence of intermediate complexes in the 5.1-7.4 S range. As demonstrated in Figure 43 panel C with an equimolar concentration of PAI-1 and vitronectin at 1.6 µM, only 6 % of
the total reaction mixture is present in the higher-order complexes with s-values above 7.5 S.
This contrasts with the mixtures containing the 8 µM and 3.2 µM concentrations, which
showed complexes in this range equal to 50 % and 30% of the total mass, respectively (Table
4-II).

The decrease in the abundance of sedimenting species with s-values greater than 7.5 S in the
more diluted mixtures is mirrored by the accumulation of intermediate species at ~6 S. For
example, in the 1.6 µM equimolar mixture, with only 6% of the total mass sedimenting as
higher-order species, a full 64 % of the total mass loaded corresponds to species in the
intermediate s-range of 5.1-7.4 S. A similar distribution of species was observed when
the mixture of PAI1/vitronectin was further diluted to ~400 nM, approaching the detection
limit of the analytical ultracentrifuge. When comparing the samples measured at the
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highest concentration to more dilute samples, peaks in the c(s) distribution at intermediate
sedimentation values from 5.1-7.4 S vary in peak width and position. For example, the
species observed at ~6.5 S in the 8 uM equimolar mixture shifts to a broader peak with a
maximum near ~6 S at lower protein concentrations tested. As discussed below, this
sedimentation coefficient of ~6 S represents a mixture of 1:1 and 2:1 PAI-1/vitronectin
complexes that are not resolved in this experiment. Because of the apparent interdependence of
species with intermediate (5.1 to 7.4 S) and high (7.5 to 25 S) sedimentation coefficients, we
focused on characterizing the composition of the intermediate species in further
experiments.

Formation of Higher-Order Complexes Occurs in a Concentration-Dependent
Fashion—To test the concentration dependence of the assembly of oligomeric
complexes, SV analysis was performed on mixtures where one of the proteins was held
constant while the other was varied. For one set of experiments (Figure 4-4, panel A),
vitronectin was maintained at a constant concentration of 1.6 µM. This particular
vitronectin concentration leads to the assembly of a predominant species in the
intermediate range with a sedimentation coefficient near 6 S (Figure 4-3). Furthermore,
this concentration is physiologically relevant and reflects the levels of vitronectin found
in normal circulation [88,89,181]. As shown in Figure 4-4, panel A, increases in the
molar concentration of PAI-1 relative to vitronectin alter the c(s) distributions, with
several higher-order complexes that form at high concentrations of PAI-1.
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Fig. 4-4. SV analysis to evaluate the concentration dependence of formation of
higher-order PAI-1/vitronectin complexes. PAI-1 and vitronectin were mixed
under conditions where the concentration of one protein was held constant while the
other was varied. The proteins were mixed for 1 h and were analyzed by SV at
50,000 rpm at 20 °C with detection by interference optics. Data were analyzed using
SEDFIT. Panels A and B show c(s) distributions for mixtures of 1.6 µM vitronectin
with 0.4 µM PAI-1 (black line), 1.6 µM PAI-1 (blue line), and 5.6 µM PAI-1 (red
line). Panel B gives an expanded view of the c(s) distribution between s values of
4.5-15 S. An asterisk denotes the critical 6.5 S complex. Panel C shows the
converse titration in which PAI-1 was held constant at 3.5 µM and the vitronectin
concentration was varied between 0.87 µM (black line), 1.7 µM (blue line), and 7 µM
(red line).
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A clearer picture of this dose-dependence is seen in Figure 4-4 panel B, which focuses
more closely on species distributed between 4.5-15 S. A sub-stoichiometric molar ratio
of PAI-1 to vitronectin (1:4) results in the assembly of complexes primarily distributed
between ~5 and 7 S. When PAI-1 is mixed with vitronectin at equimolar levels, a
significant increase in complexes in this range is evident. Moreover, the partial
resolution of the broad peak between 5-7 S into a peak at ~5.5 S and a shoulder at 6.5 S is
noteworthy. These species appear to represent PAI-1/vitronectin complexes with molar
stoichiometries of 1:1 and 2:1, respectively (Table 4-I and see next section). Also, some
higher-order species with s-values greater than 7 S emerge in this mixture. A further
increase in PAI-1 concentration to a molar ratio of 4:1 results in further re-distribution of
sedimenting species that is quite dramatic. First, the broad peak becomes more resolved
with a predominant peak at ~6.5 S, and a corresponding decrease in the ~5.5 S complex.
Thus, the 2:1 PAI-1/vitronectin complex is favored at higher PAI-1 concentrations.
Secondly, at this point there is an accumulation of significant levels of higher-order
species with s-values greater than 7 S. Multiple higher-order complexes are present,
including those at s-values of 8.7 S, 12.9 S, 16.4 S, 20.7 S, and greater. Thus, it appears
that appreciable formation of these higher-order complexes is only seen when the
intermediate 6.5 S complex is populated.
An experiment also was performed in which the PAI-1concentration was fixed and
vitronectin was varied. As shown in Figure 4-4 panel C, accumulation of PAI1/vitronectin complexes depends on the relative abundance of the two proteins. The
results of this experiment are similar to those in Figure 4-4 panel A, in which higher
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protein concentrations lead to the population of a 6.5 S complex and a concomitant
generation of higher-order complexes. Although the formation of higher-order
complexes at the highest protein concentrations is apparent, the abundance of these
complexes relative to total protein is less than observed at the highest protein
concentrations measured in Figure 4-4 panel A. This is an expected result since the
highest protein concentrations in Figure 4-4 panel C correspond to excess vitronectin, i.e.
experimental conditions that favor primarily the occupation of the high-affinity PAI-1binding site rather than the second, lower-affinity site on vitronectin. As a result, there is
less accumulation of the 6.5 S (2:1) intermediate and pursuant higher-order species,
compared to the highest protein concentrations in Figure 4-4 panel A in which PAI-1 is in
excess and both binding sites on vitronectin are occupied. The analyses of varying
protein ratios in Figure 4-4 support a mechanism for the accumulation of higher-order
species (>7.5 S) via formation of the 6.5 S species as an intermediate.

Multi-Signal Sedimentation Velocity Analysis Confirms the Binding of Two PAI-1
Molecules to Vitronectin—What is this critical complex that sediments with an s-value
of 6.5 S? Our hypothesis is that it is a 2:1 complex with 2 molecules of PAI-1 bound to
distinct sites on a single molecule of vitronectin (Table 4-I). We suggest that these two
sites on vitronectin differ in affinity, with the high affinity site (Kd ~ 1 – 10 nM [23,27])
resident in the SMB domain and a second lower affinity site (Kd ~ 25-50 nM (Chapter 2
[128] and Schar, C. S., and Peterson, C. B., unpublished data) located outside the SMB
region at a yet unidentified locus. Because of the differences in affinity, these binding
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sites should be occupied in a concentration-dependent fashion, and our SV results support
this notion. Furthermore, we hypothesize that it is the saturation of both binding sites
that forms the crucial 2:1 complex that then serves as a physiological “trigger” to induce
the formation of higher-order PAI-1/vitronectin complexes. To test this hypothesis, a
definitive identification of the composition and stoichiometry of this 6.5 S complex is
needed.
For this purpose, we have used a new multi-wavelength approach that allows
simultaneous analysis of each protein in the complex [177]. We have performed a global
analysis of multi-signal SV data for unraveling the populations and stoichiometries of
heterogeneous protein complexes formed between PAI-1 and vitronectin. We have
focused our attention primarily on the species identified at ~6.5 S. Multi-wavelength
analysis has been used fruitfully with this system of interacting proteins in our prior
sedimentation equilibrium measurements [127], taking advantage of different absorbance
properties for proteins selectively labeled with chromophores. In a similar strategy, the
SV analysis was carried out using labeled PAI-1 and/or labeled vitronectin by collecting
absorption and interference optical data from the same cell.
Both PAI-1 and vitronectin were individually labeled with fluorescein for separate
experiments. For our initial analysis, c(s) distributions were calculated using SEDFIT.
The resultant peaks were integrated, and the equivalent loading signals of the
corresponding species were compared. The results of this approach are shown in Figure
4-5, showing c(s) distributions calculated from an SV experiment monitoring a mixture
of FITC-vitronectin and unlabeled PAI-1. From interference data, the resolution of the
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Fig. 4-5. Multisignal analysis of complex formation between fluorescentlylabeled vitronectin and PAI-1 using SEDFIT. PAI-1 (8 µM) and fluoresceinlabeled vitronectin (2 µM) were mixed for 1 h and analyzed by SV at 50,000 rpm and
20 °C. Both interference and absorbance data were collected. Absorbance was
measured at 490 nm to monitor the sedimentation of fluorescein-labeled vitronectin,
whereas interference was used to monitor both proteins. As shown here, initial
analysis was carried out by individually fitting both sets of optical and absorbance
data using SEDFIT. c(s) distribution profiles for interference (solid line) and
absorbance (dashed line) data demonstrate the formation of a dominant species at ~6
S. Integration over an s range of 5.5-7 S (bracket) using both data profiles was
carried out to estimate the molar amounts of PAI-1 and vitronectin.
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5.5 S and 6.5 S species is apparent. However, the absorbance data arising from the label
on vitronectin is not resolved into two separate peaks in this analysis. This lower
resolution for the absorbance data compared to the interference data is a direct result of
the data acquisition rate for the two different types of data, since individual interference
scans are collected in ~10 sec, while each absorbance scan requires several minutes for
acquisition. An overlay of the two signals indicates that vitronectin is present in both the
5.5 S and 6.5 S complexes, and the ratio of integrated signals should reflect the molar
ratio of the species in the complexes formed. This measurement in the range of 5.1-7 S
showed that species with these sedimentation coefficients had an average molar ratio of
PAI-1:vitronectin of 1.5:1, but calculation of stoichiometries of the separate 5.5 S and 6.5
S species could not be achieved due to the resolution limits in the absorbance
measurements.
Therefore, a method was developed to globally analyze the data using multiple signals
measured simultaneous during the sedimentation experiment to discriminate the
composition and stoichiometry of species within the 5.1 – 7S range. The analysis was
implemented in the program SEDPHAT, for which features are described in detail
elsewhere [177]. From a global multi-signal analysis, the new method permits a direct
calculation of the separate c(s) distributions of the different protein components, termed
ck(s), based on the pre-determined contributions of each protein to all of the observed

signals [177]. The analysis shown in Figure 4-6, was performed on data acquired using
fluorescein-labeled vitronectin and unlabeled labeled PAI-1 (Figure 4-6 panels A and B,
interference and absorbance data, respectively). Both sets of data were globally fit by the
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Fig. 4-6. Global multisignal analysis of a PAI-1/vitronectin mixture using
SEDPHAT. Mixtures of PAI-1 (8 µM) and fluorescein-labeled vitronectin (2 µM)
were incubated for 1 h and analyzed by SV at 50,000 rpm at 20 °C. Both
interference and absorbance scans were taken every 4 min in the analytical
ultracentrifuge. Resulting profiles were analyzed using a noval multisignal analysis
feature implemented in the program SEDPHAT. Prior experiments were carried out
to determine the chromophroric and interference-coupled extinction coefficients,
which were included in the analysis. SV data, with fits to each data set, are shown
for interference (panel A) and absorbance (at 494 nm, panel B) data. Vertical green
lines in both panels represent the boundaries on data included in the global analysis.
Resulting residuals for each analysis are given below each SV data set.
Representative results for global analyses are shown in Figs 4-7 and 4-8.
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multi-signal/wavelength analysis approach using experimentally determined values
representing both chromophoric and interference-coupled extinction coefficients. Analyses
resulted in well-fit data for the experiments, with both local and global errors in the acceptable
range, as shown in the residuals below the data. Similar results were obtained from the
analysis using the opposite labeling strategy with fluorescein-labeled PAI-1 and unlabeled
vitronectin (data not shown).
The analysis of the mixture using fluorescein-labeled vitronectin and unlabeled PAI-1 shows
both protein components in co-sedimenting peaks, as expected since they form
complexes (Figure 4-7). The relative amounts of signal indicate that the complex with a
sedimentation coefficient of ~6.5 S contains a molar excess of PAI-1, and integration of
the peak areas in this c(s) distribution shows that this 6.5 S complex contains a molar ratio of
2:1 PAI-1/vitronectin. The calculation of this molar ratio relies on the relative heights of
the boundaries of the sedimenting components detected using the two signals from
interference and absorbance optics. Thus, the multi-wavelength approach explicitly
identifies the 2:1 intermediate that is required for assembly to higher-order species. Also,
the higher-order species that exhibits a sedimentation coefficient of ~8S (Figure 4-7)
contains the same molar stoichiometry of vitronectin and PAI-1, identifying this species as the
4:2 complex (Table 4-I). The same approach applied to other higher-order complexes was
less definitive (mainly due to their limited abundance and small contribution in the visible
absorbance signal) but clearly indicated the presence of molar excesses of PAI-1 in several
cases (data not shown).
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Fig. 4-7. Multisignal analysis demonstrates the formation of a 2:1 PAI1/vitronectin complex at 6.5 S. Representative multisignal analysis using
SEDPHAT with the distribution of PAI-1 and vitronectin represented by red and blue
lines, respectively.
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A detailed interpretation of the peak shapes from this multi-wavelength analysis is not
possible currently, due to probable effects of the signal/noise ratio on the degree of
regularization in the calculated curves, and the potential influence of slight mismatches in
the meniscus position of the different data sets. It should be noted that in theory the
component ck(s) distributions of interacting species can not necessarily be expected to be
in perfect register, due to the effects of finite reaction kinetics (J. Dam, C.A. Velikovsky,
R.A. Mariuzza, C. Urbanke, P. Schuck, manuscript submitted), and the dispersion of
composition in the reaction boundary predicted by Gilbert-Jenkins theory [182] which
can apply to c(s) distributions (J. Dam and P. Schuck, manuscript submitted). Despite
these effects, the integral over the peaks of the reaction boundary reports the
stoichiometry of the complexes. Thus, the multi-signal analysis provides conclusive
evidence that PAI-1 and vitronectin interact to form a 2:1 complex that sediments at ~6.5 S,
supporting our hypothesis that formation of a 2:1 PAI-1/vitronectin complex serves as a
building block in the formation of higher-order oligomers.

Oligomeric Forms of Vitronectin Persist at Long Incubation Times—PAI-1 is a
unique member of the serpin family that spontaneously converts over time to a latent,
non-inhibitory conformation [77,183]. This conformational change in PAI-1 also renders
the protein incapable of binding to vitronectin [184]. To evaluate the effects of this
transition to latent PAI-1 on the distributions of higher-order complexes, a time course
was evaluated over > 24 hours. In these experiments, equimolar mixtures of PAI-1 and
vitronectin were incubated at room temperature for different time intervals and then
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subjected to SV analysis. As shown in Figure 4-8, c(s) distributions for mixtures
incubated at 1 hour and 6 hours are similar, with a near equivalent population of the
species at ~6.5 S. However, there is a redistribution of higher-order species with s-values
greater than 7.5 S, most apparent for the species with a sedimentation coefficient ~8 S
(Table 4-I). It is probable that this redistribution reflects an accumulation of higher-order
forms that assemble on a longer time scale than the 2:1 intermediate at ~6.5 S.
As incubation times are increased to 12 and 24 hours, there is further re-distribution,
with a time-dependent loss of higher-order species. These changes are attributed to
dissociation of the complexes as PAI-1 is converted to the latent form that does not bind
to vitronectin [184]. Consistently, the time-dependent loss of higher-order species
correlates well with the rate at which PAI-1 converts to a latent form under these
conditions [163]. Also consistent is the loss over time of the ~6.5 S (2:1) intermediate,
coincident with the accumulation of significant amounts of free vitronectin and latent
PAI-1. In agreement with work described in Chapter 2 [119,128], some oligomeric
forms of vitronectin persist, even at the longest times that correlate with complete loss of
active PAI-1. Indeed, almost 44 % of the total loading signal for vitronectin was still
present as oligomers after 24 hours.

Salt Effects Demonstrate the Potential Role of Ionic Interactions In the Formation of
a Vitronectin/PAI-1 Complex—Mixtures of vitronectin and PAI-1 were made in the
presence of increasing concentrations of sodium chloride and tested for complex
assembly using sedimentation velocity. Results shown in Figure 4-9 demonstrate the
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Fig. 4-8. Test for the formation of vitronectin oligomers as a function of time..
PAI-1 and vitronectin were mixed at equimolar concentrations of 3.3 µM and
incubated at room temperature for various amounts of time and then analyzed by SV
at 50,000 rpm at 25 °C using interference optics. c(s) distributions at 1 h (blue line),
6 h (red line), 12 h (green line), and 24 h (black line) time points are shown.
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Fig. 4-9. Test for the effects of NaCl concentration on the formation of PAI1/vitronectin complexes. Equimolar mixtures of vitronectin and PAI-1 were
incubated at room temperature in PBS containing various amounts of NaCl: 150 mM
(black line), 250 mM (blue line), and 500 mM (red line) NaCl concentration.
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reversibility of the 6.5 S vitronectin/PAI-1 complex to a slower-sedimenting species of
~5.5 S at a salt concentration of 500 mM NaCl. From these results, we speculate that the
5.5 S and 6.5 S species observed here represent complexes of 1:1 and 1:2
(vitronectin:PAI-1) stoichiometries, respectively, and that the salt effects demonstrate the
importance of ionic interactions in maintaining a 1:2 molar ratio.

Assembly of PAI-1/Vitronectin Complexes is Independent of the Anti-Protease
Activity of the Inhibitor—Is the spontaneous conversion of PAI-1 to a latent
conformation required for accumulation of vitronectin oligomers that persist at long
times, as shown in Figure 4-8? Must PAI-1 be active as a protease inhibitor to be
effective in promoting the formation of higher-order complexes? To address such
questions, mutant forms of PAI-1 were used that exhibited either slower rates of
conversion to the latent form [158,168] or impaired anti-protease activity [169]. Several
forms of PAI-1 have been engineered by introduction of strategic mutations that disfavor
conversion to a latent structure and thus allow PAI-1 to retain activity for a long period of
time.
Analysis of a stable form of PAI-1, the W175F mutant [168], gave a common c(s)
distribution pattern of PAI-1/vitronectin complexes induced by W175F versus wild-type
PAI-1 (Figure 4-10), with the distribution of species in the 1-5 S, 5.1-7.4 S and >7.5 S
ranges summarized in Table 4-III. It is clear from the results on this “stable” mutant that
the inherent rate of conversion to a latent form is not a critical feature that determines the
ability of PAI-1 to form higher-order complexes with vitronectin.
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Fig. 4-10. c(s) distribution analysis of equilmolar mixtures of mutant forms of
PAI-1 and human vitronectin. Equilmolar amounts of wild-type PAI-1 (3.2 µM) or
mutant PAI-1 (3.3 µM) and vitronectin were mixed for 1 h and were analyzed by SV
at 50,000 rpm at 25 °C using SEDFIT. Resulting c(s) distributions are shown in
panels A-D for mixtures of vitronectin and wild-type PAI-1 (black lines), stable
mutant 14-1B PAI-1 (green lines), stable mutant W175F PAI-1 (red lines), and noninhibitory PAI-1R (blue lines). Panels B and D give expanded plots of distibutions
shown in Panels A and C, respectively, for s values between 8 and 22 S to focus in
on higher-order complexes formed.
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Table 4-III: Assembly of complexes between different recombinant forms of PAI-1
a
and vitronectin.

Samples

Protein
Concentrations

Unbound
Intermediate Higher-Order
Proteins
Complexes
Complexes
(Fraction in s- (Fraction in s- (Fraction in srange from 1- range from 5.1- range from 7.5b
b
b
5 S ), %
7.4 S ), %
25 S ), %

3.2 µM Vitronectin
c
3.2 µM PAI-1
Vitronectin + 3.3 µM Vitronectin
Y175F PAI-1 3.3 µM PAI-1
Vitronectin +
wt PAI-1

25

45

30

25

34

41

Vitronectin +
PAI-1R

3.3 µM Vitronectin
3.3 µM PAI-1

20

40

40

Vitronectin +
14-1B PAI-1

3.3 µM Vitronectin
3.3 µM PAI-1

31

44

25

a

Ranges in s -values were defined for integration according to criteria outlined in
Table 4-I, with species sedimenting with s -values in the range from 1-5 S
representing free proteins, species with s -values in the range from 5.1-7.4 S
representing intermediate 1:1 and 2:1 (PAI-1:vitronectin) complexes, and species
sedimenting with s-values greater than 7.5 S representing higher-order complexes.
b
Sedimentation data were evaluated as c(s) profiles, and data were integrated using
SEDFIT to determine the relative amounts of various PAI-1/vitronectin complexes
formed. Values were normalized by dividing the integrated values by the total
loading signal in fringes, and multiplying by 100 to obtain a percentage of the
various species formed. Errors are ± 5%.
c
C(s ) distributions of complexes with s-values >5 S for the three concentrations of
vitronectin and wild-type PAI-1 samples are shown in Figure 4-3, panels B-D.
Free proteins that sediment in the 1-5 S range are not shown in the figure, but the
integrations over this s -range are shown here.
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Another PAI-1 mutant tested in these experiments was the non-inhibitory mutant PAI1R [169]. This double arginine mutant (T333R and A335R) is impaired in its ability to
act as an inhibitor of either tPA or uPA due to the introduction of charges into strategic
positions in the reactive center loop that impede the insertion of this reactive center loop
into the central β-sheet of the protein upon cleavage by plasminogen activators [169].
However, this mutant PAI-1 retains the ability to bind vitronectin. The structural changes
result in PAI-1R acting as a substrate, not an inhibitor, for plasminogen activators; as
such, this mutant serves as a valuable tool for studying a variety of non-proteolytic roles
of PAI-1 that are important during processes like cell migration and tissue remodeling
[135,138,185,186]. As summarized in Table 4-III, PAI-1R induces a similar formation of
higher-order species as wild-type PAI-1. These findings indicate that the ability of PAI-1
to promote the formation of higher-order complexes with vitronectin is independent of its
ability to inhibit plasminogen activators.
Because of potential experimental complications that may arise due to the inherent slow
rate of conversion to latency by native PAI-1, many researchers have opted in their
studies to use the stable variant of PAI-1 that has been best characterized [157,158] This
PAI-1 variant, denoted 14-1B, contains 4 mutations (Asn150His; Lys154Thr; Gln319Leu;
Met354Ile) and is the form of PAI-1 that has been crystallized [160]. These mutations
result in a delay in the transition of PAI-1 to latency by approximately 70-fold, with no
reported change in inhibition of tPA or uPA. Although many current structural and
functional studies rely on the use of the stable 14-1B PAI-1, it appears that there are some
distinctions between native PAI-1 and the stable conformer. For example, uPA reacts
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differently with native PAI-1 and the 14-1B variant in the presence of the non-ionic
detergent Triton X-100, with a reduction in the inhibitory activity against both forms
[161]. Because of the possibility that there may be important structural and/or functional
differences, the stable 14-1B variant was compared to native PAI-1 in the fibroblast
binding assay.

Discussion
Arguably, the most important physiological ligand of vitronectin is PAI-1. Vitronectin
stabilizes PAI-1 in its active conformation, and as an adhesive protein, serves to localize
PAI-1 inhibition at specific sites of tissue damage. PAI-1 binding to vitronectin results in
profound conformational rearrangements, which subsequently result in the formation of
multimeric structures with binding properties different from that of monomeric
vitronectin [119,127]. Multimeric forms of vitronectin have been shown to readily
associate with both cell surface receptors and ECM components [47,61,118,119,129132], indicating that multimerization in vivo might be the key step leading to the
conversion of vitronectin to a matrix-associated form. Importantly, both vitronectin and
PAI-1 have been detected co-locally with tissues undergoing wound healing or tumor
metastasis [102,111,123-126], suggesting that the two proteins serve as co-factors in
matrix deposition and remodeling.
The mechanism through which vitronectin and PAI-1 assemble to form complexes that
display adhesive properties at the cell-matrix interface is unknown. Earlier reports from
this lab and others demonstrated that vitronectin binding to PAI-1 leads to the occupation
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of two distinct PAI-1-binding sites on vitronectin, and this event leads to the building of
higher-order complexes [119,127,128]. Sedimentation equilibrium studies using
analytical ultracentrifugation to evaluate vitronectin/PAI-1 complexes demonstrated the
formation of a large (~300 kDa) intermediate species consisting of 4 molecules of PAI-1
bound to 2 molecules of vitronectin [127]. These higher forms of vitronectin/PAI-1
complexes are adhesive in nature, and through multivalent interactions rapidly associate
with cell surfaces and the ECM [123,128].
The goal of this study was to add additional information regarding complex formation
between vitronectin and PAI-1 to better understand the assembly process and identify the
types of higher-order complexes that form. Equilibrium studies evaluating the binding of
vitronectin to the fluorescently-tagged NBD-S119C-PAI-1 resulted in sigmoidallyshaped binding isotherms indicative of an allosteric event. Data fits to the Hill equation
indicated that allosteric binding between vitronectin and PAI-1 leads to the occupation of
two PAI-1-binding sites. This is in agreement with studies from this lab using
sedimentation equilibrium and competition studies using site-specific monoclonal
antibodies [127].
Sedimentation velocity experiments provide valuable information regarding the stepwise assembly of higher-order species that form when vitronectin interacts with PAI-1
over time. These findings show a strong dependence on PAI-1 concentration on the sizes
of vitronectin/PAI-1 complexes that form. Some complexes were shown to be dependent
on ionic strength, in particular a complex that most likely represents a 1:2
vitronectin/PAI-1 species. Time-course studies provide information regarding the
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reversibility and long-term survival of assembled complexes, especially those that remain
even after PAI-1 has converted to the latent, non-vitronectin binding form. Combining
this information with our previous findings, we can develop a working model that helps
describe the assembly process leading to the step-wise formation of higher-order
vitronectin/PAI-1 complexes that are functionally important, Figure 4-11 shows the
schematic of a working model describing the assembly of vitronectin/PAI-1 complexes.
In this model, PAI-1 first associates with a high-affinity binding site (SMB domain) on
vitronectin and forms a 1:1 complex. Binding of PAI-1 to the first site has an allosteric
effect on a second PAI-1-binding site that results in the formation of a 1:2
(vitronectin:PAI-1) stoichiometric complex. Recent evidence from stopped-flow studies
using fluorescence quenching demonstrates that the formation of the 1:2 complex, a slow
PAI-1-independent step (first-order rate constant of 0.04 sec-1) that reflects a
conformation change in vitronectin (manuscript in preparation). This conformationally
perturbed 1:2 vitronectin/PAI-1 complex is prone to self-association and serves as the
building scaffold for higher-order complexes. Throughout the assembly process, PAI-1
is cycled on and off the complexes that form, and over time slowly exits the process
following its conversion to latency. At very long times, only stable vitronectin multimers
remain, with a significant population returning to the monomeric form.
Future studies are required to help clarify and expand on the model presented in Figure
4-11. Very recent stopped-flow experiments performed by our collaborator Dr. Grant
Blouse at Henry Ford Health Systems in Detroit define second-order rate constants of 2 x
106 M-1sec-1 and 7.6 x 106 M-1sec-1 for the first two binding events that occur between
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4.2 S

5.5 S

6.5 S

6.5 S

≥ 10 S

~8 S
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+
PAI-1

n

3.4 S
Slow release of latent PAI-1
over time

Accumulation of stable VN
oligomers

+
n

Fig. 4-11. Model for formation of multivalent complexes via the 6.5 S PAI-1/vitronectin intermediate. In
this model, PAI-1 (blue circles with black, exposed loop) binds to vitronectin (red ovals) in a concentrationdependent manner to form important intermediate 1:1 and 2:1 PAI-1/vitronectin complexes. A conformational
change producing “activated” vitronectin is indicated by the conversion of vitronectin to a structurally altered
form (red stars). Activation of vitronectin is coupled with oligomerization, leading to the assembly of the 4:2
PAI-1/vitronectin complex and additional higher order species. Over the course of time, there is slow release of
latent PAI-1 (blue circle with white, buried loop) which is possibly released from any of the various
intermediates formed and cannot associate with vitronectin. Structural activation of vitronectin is also associated
with the accumulation of stable higher-order vitronectin oligomers over time.
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vitronectin and PAI-1. Both events are PAI-1-dependent and are followed by a
conformational change in vitronectin, as discussed above, that leads down the path of
higher-order assembly. Additional techniques that are currently being used to address
our assembly model include fluorescence anisotropy, fluorescence energy transfer
(FRET), and CD spectroscopy. In addition, more sedimentation velocity experiments will
be applied using mult-signal detection systems and global analysis to determine the molar
stoichiometries of vitronectin/PAI-1 complexes in c(s) distributions to better characterize
the types and sizes of higher-order species that form. Structural studies like neutron
scattering and high-resolution electron microscopy will aid in understanding the physical
properties of higher-order complexes. Finally, by combining information gained from
the studies described above, especially those coming from analytical ultracentrifugation,
stopped-flow kinetics, and fluorescence polarization, we can use computer algorithms to
simulate the assembly process of complex formation and be able to predict the effects of
varying parameters, such as PAI-1 concentration. As PAI-1 levels in circulation are
much lower than we can use in our experimental approaches to obtain usable signals, we
can instead predict the formation of vitronectin/PAI-1 complexes using simulations based
on more physiological concentrations of PAI-1. Studies like these are important when
considering the potential dependence that processes like tumor growth and angiogenesis
have on local PAI-1 concentrations [165,187].
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